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The liver and pancreas originate from common endodermal progenitors in early 
development. Single-cell lineage tracing experiments using zebrafish model system have 
demonstrated that Bone morphogenetic protein 2b (Bmp2b) signaling is essential in 
determining the fate of these bipotential progenitors towards the liver or pancreas. 
However, key downstream targets in the Bmp2b signaling regulatory network remains 
largely unknown. Therefore, we performed transcriptome analyses to identify genes that 
respond to altered levels of Bmp2b signaling. We found four and a half LIM domains 1b 
(fhl1b) as a novel target of Bmp2b signaling. fhl1b is primarily expressed in the 
prospective liver primordium. By loss of fhl1b using morpholino and overexpression of 
fhl1b combined with single cell lineage tracing, we showed fhl1b favors the specification 
of liver and suppresses the induction of pancreatic cells. These data reveal novel and 
critical functions of Fhl1b in regulating the hepatic versus pancreatic fate decision as a 
Bmp2b downstream target. 
Diabetes is characterized by compromised glucose regulation. Both type 1 and 
type 2 diabetes patients suffer from losing functional β-cells along the progression of the 
disease. Given its function in suppressing pancreas induction with concomitant 
stimulation of liver, we conducted loss- and gain-of-function studies of fhl1b using a 
zebrafish model of type 1 diabetes. We conclude that fhl1b regulates the regeneration of 
β-cells mainly via modulating ductal progenitor-to-β-cell neogenesis. In addition to 
Bmp2b signaling pathway, we identified inhibitors of non-canonical IκB kinases, TANK-
binding kinase 1 (TBK1) and IκB kinase ε (IKKε), as enhancers of β-cell regeneration. 
 xii 
TBK1/IKKε inhibitors promoted β-cell regeneration through enhancing β-cell-specific 
proliferation. Our results also suggested that this effect is achieved by up-regulating 
cAMP levels via suppressing activation of Pde3a in zebrafish. TBK1/IKKε inhibitors 
augmented function and proliferation of β-cells in mammalian islets including human 
islets in vitro. TBK1/IKKε inhibitors also improved glycemic control in streptozotocin 
(STZ)-induced diabetic mice with increased β-cell proliferation, and total insulin content 
in vivo. Therefore, our work shows an evolutionarily conserved and critical role of 
TBK1/IKKε suppression in expanding functional β-cell mass, and a strong clinical 
potential of TBK1/IKKε suppression in diabetes treatment. 
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CHAPTER 1  
INTRODUCTION 
The liver and pancreas are two essential organs regulating glucose metabolism. 
Cells residing in them produce hormones and enzymes in response to environmental 
signals inside the body, to facilitate maintaining physiological homeostasis. In pancreas, 
endocrine cells are clustered together, forming pancreatic islets. These tiny structures are 
engulfed in exocrine pancreatic cells, and only constitute a very small portion of the 
entire organ. However, hormones secreted by endocrine cells, especially glucagon and 
insulin, play key roles in controlling glucose levels. Endocrine cells, including glucagon-
producing α-cells, insulin-producing β-cells, somatostatin-producing δ-cells, produce 
functionally distinct hormones to balance glucose production and storage in body. The 
majority of pancreas consists of exocrine cells. The exocrine cells, along with hepatic 
cells, generate digestive enzymes, that are transported by ductal system to intestine to 
assist ingesting nutrients. Among these various types of cells, the insulin-secreting β-cells 
have continuously been the focus of researches in academia, and of topics in general 
media, due to their direct association with the development of diabetes.  
Diabetes is characterized by compromised glucose regulation. Both type I and 
type II diabetes patients suffer from losing functional insulin-producing β-cells along 
progression of the disease. However, the symptoms can be ameliorated by simply 
replenishing the pancreas with functional β-cells. One current approach is to transplant 
functional β-cells to patients, which heavily relies on the availability of cadaver donors. 
This approach faces many drawbacks. Besides the scarcity of donors, lifelong 
immunosuppression may be required, which usually leads to adverse effects (Cogger and 
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Nostro, 2015). Hence, developing alternative sources for high-quality, and ideally, 
compatible β-cells has become the mission of many studies. One intensively explored 
direction of these researches is to induce embryonic stem cells (ESCs) to differentiate 
into functional insulin-producing β-cells. Combining with patient-specific induced 
pluripotent cells, this strategy could easily generate sufficient material in vitro for 
transplantation, with no immunosuppression treatment necessary. Therefore, 
understanding the regulatory signaling pathways during normal organogenesis can be 
exploited to optimize the current protocol, benefiting the promotion of cell-based 
transplantation for diabetes treatment. Another promising direction for diabetes treatment 
is to enhance the expansion of functional β-cells. For patients with less severe loss of β-
cells, expanding the remaining functional β-cell population in vivo could be one of the 
easiest and least costing methods. In addition, transplantation-based treatment will also 
benefit from increased proliferation of β-cells during in vitro culture to prepare sufficient 
supplies, and during and after operation to achieve higher therapeutic efficiency.   
.  
1.1  Pathways in normal development of liver and pancreas 
After gastrulation, the three primary germ layers are segregated. The endodermal 
cells continuously migrate to form a tube-like structure, before the budding of digestive 
organ primordia. Meanwhile, these endodermal cells are highly plastic and competent. 
The fate of these cells are delicately regulated by the signals and cues produced from 
surrounding mesenchymal tissues, orchestrating the following patterning and 
organogenesis (Wells and Melton, 2000; Zorn and Wells, 2009). For liver and pancreas 
specification and development, the patterning of foregut endodermal region is critical to 
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ensure the proper differentiation of functionally diverse cell types. The anterior-posterior 
and dorsal-ventral patterning for the following organogenesis is finely controlled by 
many growth factor signaling pathways, including Wnt (Lancman et al., 2013; McLin et 
al., 2007; Ober et al., 2006), fibroblast growth factor (FGF) (Shin et al., 2011; Shin et al., 
2007), bone morphogenetic protein (BMP) (Chung et al., 2010; Chung et al., 2008; Shin 
et al., 2007; Zaret, 2008), retinoic acid (RA) (Kinkel et al., 2008; Ostrom et al., 2008; 
Stafford and Prince, 2002), hedgehog (Hh) (Chung and Stainier, 2008; diIorio et al., 
2002), and Notch (Murtaugh et al., 2003; Ninov et al., 2012; Shih et al., 2012).  
Studying the early development of liver and pancreas sheds light in our 
understanding of the onset of certain congenital diseases, the impaired structure and 
function of tissues and organs involved in these diseases, and providing potential 
treatment clues. Furthermore, the rapidly thriving approach of using in vitro induction 
and culture to produce sufficient functional cells from ESCs or pluripotent cells, to 
supply transplantation-based disease treatment, is also taking advantages of the 
accumulated understanding of early development. Many induction protocols have been 
developed and successfully generated insulin-producing β-cells. These protocols use 
signaling molecules to guide the differentiation path of ESCs, mimicking endogenous 
dynamics of changing pathways shaping the fates of progenitor cells (Pagliuca et al., 
2014; Rezania et al., 2014; Russ et al., 2015). 
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1.2  Pathways in pancreatic β-cell regeneration 
Unlike the robust regenerative capacity of liver, through proliferation of abundant 
hepatocytes or activation of progenitor cell population in the ductal system (Huang et al., 
2014; Michalopoulos, 2007), the spontaneous regeneration of pancreatic β-cells is weak. 
Previous studies have shown that -cell regeneration can be promoted by either 
enhancing the proliferation of residual -cells (Dor et al., 2004) or stimulating neogenesis 
of -cells from non--cells. Non--cells could be progenitor cells residing in the extra- 
and/or intra-pancreatic ductal systems (Xu et al., 2008) or other mature cell types 
including glucagon-expressing -cells (Thorel et al., 2010) or digestive enzyme-secreting 
acinar cells (Zhou et al., 2008). Although the regulatory network controlling pancreatic 
-cell development is well-explored (Arda et al., 2013; Pan and Wright, 2011), the 
signaling pathways mediating -cell regeneration remain largely unknown. Recently, the 
Adenosine signaling pathway has been shown to increase -cell proliferation during 
homeostasis and regeneration (Andersson et al., 2012; Annes et al., 2012). In addition, 
the growth factor (insulin/IGF-1) signaling pathway and NFAT-DYRK1A signaling were 
reported to be activated to promote β-cell proliferation (El Ouaamari et al., 2015; Wang 
et al., 2015a). Nevertheless, few studies have pinpointed extrinsic signaling pathways, 
including Bmp signaling, that can induce de novo formation of -cells during 
regeneration with a limited focus on determining the origin of newly formed -cells 
(Stanger and Hebrok, 2013; Ziv et al., 2013). More importantly, to expand the clinical 
exploration on β-cell regeneration, whether manipulating these pathways successfully 
boosts up human β-cell regeneration is an inevitable question to be addressed.  
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1.3 Diabetes and the loss of functional β-cells 
Diabetes mellitus is an epidemic healthcare challenge affecting around 380 
million people worldwide, based on the International Diabetes Federation. According to 
2014 National Diabetes Statistics Report, in the United States alone, 29.1 million people 
(9.3% of the population) have diabetes. What’s more, 86 million people are predicted to 
have prediabetes, among which 15-30% will develop type 2 diabetes within five years. 
Patients with diabetes failed to produce sufficient insulin, or use insulin effectively. As 
the disease progresses, properly functional insulin-producing β-cells are getting scarce, 
resulting in severely compromised glucose homeostasis. In addition, patients with 
diabetes are at higher risk of serious health complications, such as heart disease, kidney 
failure, and blindness.  
The direct cause of diabetic symptoms is the insufficiency or functional failure of 
insulin-producing β-cells, alone or in association with insulin resistance (Shaw et al., 
2010). However, simply replenishing the pancreas with functional β-cells is competent to 
reverse the progression. This approach has been proven fruitful and employed widely 
(Wang et al., 2015b). It also has inspired many studies to obtain new β-cells through 
converting stem-cell or transdifferentiating non-β-cells into β-cells, or to discover small 
molecules or other compounds that can induce proliferation of β-cells. Due to both 
metabolic factors and immune components are closely linked to the progression of 
diabetes (Brezar et al., 2011; Donath and Shoelson, 2011; Esser et al., 2014), coupling 
expansion and protection of residual functional β-cells is critical in remedying diabetes. 
However, few currently available approaches achieved this goal. 
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1.4  Zebrafish as a model organism for developmental/regeneration studies 
and chemical testing 
Zebrafish has been used as model organism for development for a few decades. 
The visually transparent small-sized body, ex utero development from fertilization, easy 
genetic manipulation and easy access to massive number of larvae, make zebrafish one of 
the ideal models to study early pattern and development events. The zebrafish liver and 
pancreas share their basic cell types with the mammalian liver and pancreas. All major 
types of hepatic and pancreatic cells are present in zebrafish, and they function in similar 
fashion as their mammalian counterparts. In addition, the signaling pathways that lead to 
the establishment of liver and pancreas are generally conserved from fish to mammals. 
Therefore, zebrafish provides a powerful tool to probe the mechanisms controlling 
establishment of the liver and pancreas from early embryonic progenitor cells, as well as 
the regeneration of these organs after damage. This knowledge is, in turn, applicable to 
refining protocols to generate renewable sources for clinical purposes. 
Furthermore, with the rapidly advancing genetic techniques and accumulating 
pools of resources, studies are expanding to less explored yet important aspects of human 
diseases (Dooley and Zon, 2000). After successful establishment of zebrafish models of 
human diseases, they can be used to study various sides of the disease. As vertebrate, 
zebrafish acquires complexity in physiology and behavior similarly seen in mammalian 
systems, including human. One can easily monitor the real-time changes of other cell 
types or tissue in pathogenic condition with the assistance of endogenous fluorescent 
markers. To loyally establish a zebrafish model of human disease can be tricky. Not to 
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mention some diseases are initiated by a bunch of mixed factors, or progressed tardily 
with environmental influences, many diseases are not even thoroughly understood, 
making it extremely challenging to establish a model exposed to exactly the same genetic 
and/or environmental influence. However, researchers have adopted to use strategies 
phenotypically imitating human diseases (Moss et al., 2009).  
Meanwhile, zebrafish has been embraced as a powerful platform to test and 
discover new effects of chemicals for quite some time (Rennekamp and Peterson, 2015). 
The small sized, massively reproduced population permits an economically efficient 
system for large scale screening. As vertebrate, zebrafish acquires complexity in 
physiology and behavior. The transparent body allows easy observation of changes in 
vivo. Last but not least, zebrafish is able to phenotypically imitate a wide range of 
diseases. It is also simple enough to administrate chemicals to zebrafish larvae, by 
directly adding the chemicals into the egg medium. Combining these points together, it 
makes zebrafish one of the ideal model organisms to test chemical properties.  
 
1.5 Conclusion 
Using zebrafish as a model organism to study (1) the fate decision of progenitor 
cells during normal development, and (2) β-cell regeneration embraces great advantages 
to provide insights in diabetes treatment. The loss of functional insulin-producing β-cells 
in progression of diabetes can be ameliorated by transplanting functional β-cells to 
patients, or expanding the remaining functional β-cells in vivo. In addition to traditional 
sources for transplantation, new protocols utilizing directed ESC differentiation to 
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produce supplies for transplantation have been developed based on the knowledge of 
regulatory signaling pathways during normal organogenesis, and will continuously 
benefit from more detailed and accurate understanding of this process. Easy access to 
massive zebrafish samples and convenient observation of in vivo changes in zebrafish 
models of diabetes enable expedited discoveries on new regulatory pathways and targets 
for diabetes treatment. These regeneration-specific targets could be potentially more 
efficient and safer in expanding endogenous β-cell population than strategies affecting 





CHAPTER 2  
BMP2b SIGNALING ACTIVATES FOUR AND A HALF LIM 
DOMAINS 1b (Fhl1b) TO REGULATE THE LIVER VERSUS 
PANCREAS FATE DECISION 
 
The work in this chapter contributes to the following publication:  
Xu, J., et al. (2016). PLOS Genetics. 
 
2.1 Abstract 
The liver and pancreas, two essential organs regulating metabolism homeostasis, despite 
their distinct structures, cellular composition and physiological functions, originate from 
bipotential progenitors in early endoderm. Single-cell lineage tracing experiments using 
zebrafish model system have demonstrated that Bmp2b signaling plays a critical role in 
determining the fate of these bipotential hepatopancreatic progenitors towards the liver or 
pancreas. Nevertheless, the downstream regulatory network of Bmp2b signaling in this 
process is poorly understood. In our study, we identified four and a half LIM domains 1b 
(fhl1b) as a novel target of Bmp2b signaling. fhl1b is primarily expressed in the 
prospective liver primordium. Depletion of fhl1b by morpholino compromised 
specification of liver and enhanced induction of pancreatic cells, particularly endocrine 
cells. Conversely, overexpression of fhl1b promoted specification of liver and suppressed 
induction of pancreatic cells. By single-cell lineage tracing experiments, we showed that 
fhl1b depletion led the progenies of lateral endodermal progenitor cells, destined to 
 10 
become liver cells in normal cases, to become pancreatic cells. Reversely, when fhl1b 
was overexpressed, the progenies of medially located endodermal progenitor cells, fated 
to differentiate into pancreatic and intestinal cells, turned into liver cells. Altogether, 
these data reveal novel and critical functions of Fhl1b in the hepatic versus pancreatic 
fate decision.   
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2.2  Introduction 
Bone morphogenetic protein (Bmp) signaling has been shown to be heavily 
involved in endodermal progenitor fate decision, among other signaling pathways. In 
general, Bmp signaling induces the liver at the expense of Pdx1-expressing organs and 
tissues in various animal models (Chung et al., 2008; Rossi et al., 2001; Spagnoli and 
Brivanlou, 2008; Wandzioch and Zaret, 2009; Xu et al., 2011). To activate the expression 
of liver lineage genes, Bmp signaling can regulate the expression levels of zinc finger 
transcription factor Gata4 (Rossi et al., 2001; Shin et al., 2007), and epigenetically, 
promote histone acetylation at the liver gene regulatory elements (Xu et al., 2011). On the 
other hand, Bmp signaling may actively suppress the pancreas gene expression. Pdx1 
expression was inhibited in mice half-embryo cultures treated with Bmp4 at the 3-4 
somite stage (Wandzioch and Zaret, 2009). pdx1 expression gradient is formed in 
zebrafish endodermal progenitor cells based on their relative distance from Bmp2b 
signaling. The lateral endodermal progenitors close to the Bmp2b signal show minimum 
pdx1 expression and differentiate into liver, while medial endodermal progenitors distant 
from the Bmp2b signal express high levels of pdx1 and differentiate into pancreas and 
intestine (Chung et al., 2008). Furthermore, to successfully induce PDX1 expression in 
human embryonic stem cells (hESCs) hence generate INSULIN-secreting β-cells, 
inhibition of BMP signaling is required based on recent studies and protocols (Kroon et 
al., 2008; Nostro et al., 2011; Pagliuca et al., 2014; Rezania et al., 2012). In addition, the 
induction of β-cells in zebrafish can be blocked by Bmp signaling activation cell-
autonomously (Chung et al., 2010). However, how Bmp signaling facilitates liver 
specification at the expense of pdx1-expressing cells remains to be further elucidated, 
which necessitates the identification of downstream regulatory network. Furthermore, the 
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key question of whether Bmp signaling suppresses Pdx1 expression to keep progenitors 
competent to differentiate into the liver or directly induces the liver gene program has not 
yet been answered. 
In addition to the processes in normal development, it’s been suggested that a 
progenitor cell population in the hepatopancreatic ductal (HPD) system may undergo 
differentiation upon stimuli in later stages. The HPD system connects the liver, 
gallbladder, and pancreas with the intestine, transporting products of multiple types of 
cells to the main location of nutrient ingestion. The HPD systems in amniotes and 
zebrafish are developmentally and structurally similar (Dong et al., 2007). In the HPD 
system of fgf10 and sox9 mutant zebrafish, hepatocyte-like and pancreatic-like cells can 
be observed within/adjacent to the system (Delous et al., 2012; Dong et al., 2007; 
Manfroid et al., 2012), indicating the existence of a progenitor cell population and its 
ability to differentiate into either liver or pancreas cells. Notch signaling and pdx1 
function have also been suggested to play essential roles in the induction of pancreatic 
endocrine cells from the progenitors in the HPD system of zebrafish (Kimmel et al., 
2011). Consistent with expression studies in zebrafish, that pdx1 is expressed in the HPD 
system and pancreas but not in liver (Field et al., 2003a), lineage tracing studies in 
mammals implied that the HPD system and the ventral pancreas, were derived from cells 
expressing both Pdx1 and Sox17, a master regulator of the pancreaticobiliary ductal 
system (Spence et al., 2009). Intriguingly, the expression of Inhibitor of DNA binding 2 
(Id2) protein, a cell-autonomous marker of Bmp signaling activity (Miyazono and 
Miyazawa, 2002), is excluded in the endocrine pancreas, and HPD system (Chung et al., 
2010), which are the tissues that retain the potential to form pancreatic endocrine cells. In 
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a rat pancreatic epithelial cell line, Id2 has been implicated in repressing the function of 
key pancreatic endocrine transcription factor Neurod, which is essential for endocrine 
pancreas development (Hua et al., 2006). Nonetheless, the underlying mechanisms of 
how Bmp signaling orchestrates the proper lineage choice of the progenitors in the HPD 
system await further investigation. 
The LIM (LIN-11, ISL-1, and MEC-3) domain is mediating protein-protein 
interaction without intrinsic catalytic activity (Kadrmas and Beckerle, 2004; Sang et al., 
2014). The LIM proteins often contribute to biological activity as molecular adaptors or 
scaffolds to support the assembly of multimeric protein complexes (Chang et al., 2003). 
The four-and-a-half LIM (FHL) proteins contain four complete LIM domains with an N-
terminal half LIM domain (Shathasivam et al., 2010). These proteins can be expressed in 
a cell- and tissue-specific manner to regulate cellular processes such as proliferation, 
differentiation, and adhesion/migration. However, little is known about their role in the 
cell fate choice between the liver and the pancreas.  
Here, by transcriptome analysis, we identified a novel Bmp2b target, four and a 
half LIM domains 1b (fhl1b). fhl1b is primarily expressed in the prospective liver anlage. 
Loss- and gain-of-function as well as single-cell lineage tracing analyses indicate that 




2.3 Methods and materials 
2.3.1 Zebrafish strains 
Adult fish and embryos were raised and maintained under standard laboratory conditions 
(Westerfield, 2000). All animal work was performed according to procedures approved 
by the Institutional Animal Care and Use Committee at Georgia Institute of Technology. 
We used the following published transgenic lines: Tg(P0-pax6b:GFP)ulg515 (Delporte et 
al., 2008), Tg(ins:GFP)zf5 (Huang et al., 2001), Tg(ins:dsRed)m1018 (from W. Driever, 
Freiburg), TgBAC(neurod:EGFP)nl1 (Obholzer et al., 2008), Tg(sox17:GFP)s870 (Chung 
and Stainier, 2008), Tg(hsp70l:bmp2b)f13 (Chocron et al., 2007), Tg(fabp10:dsRed, 
ela3l:GFP)gz12 (Farooq et al., 2008), Tg(-5.5ptf1a:DsRed)ia6 (Leung et al., 2011), 
Tg(ptf1a:GFP)jh1 (Godinho et al., 2005), Tg(ins:Kaede)jh6 (Pisharath et al., 2007), and 
Tg(ins:CFP-NTR)s892 (Curado et al., 2007), and Tg(fabp10a:CFP-Eco.NfsB)gt1 (Huang et 
al., 2014). To generate the Tg(hsp:fhl1b; hsp:GFP)gt3, fhl1b coding sequence was 
amplified (forward: 5’-CCGGAATTCATGGCAAGCCGGTCCAACTG-3’, reverse: 5’-
CCGGAATTCTTACAGTTTCTTGGAGCAGTCG-3’) and cloned into a vector 
containing a multimerized minimal heat shock promoter, which drives gfp and fhl1b 
transcription bi-directionally in response to a heat shock (Bajoghli et al., 2004). Tol2-
mediated transgenesis was achieved as described (Kawakami et al., 1998).   
 
2.3.2 Microarray and phylogenetic analysis 
Tg(sox17:GFP)s870 embryos were either crossed with Tg(hsp70l:bmp2b)f13 to induce 
overexpression of bmp2b at the 8-somite stage or treated with DMH1. For each 
condition, 100 embryos were used. At 20 hpf, sox17:GFP-positive endodermal cells from 
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dissected zebrafish trunks containing the organ-forming area were isolated by FACS and 
subjected to transcriptome profiling using the Zebrafish 44K gene expression microarray 
(Agilent Technologies). Data with an average fold change of 2 (bmp2b overexpressing) 
or 2.75 (DMH1-treated) at p ≤ 0.05 were considered for GO analysis using PANTHER 
(http://www.pantherdb.org/). The phylogenetic tree of zebrafish Fhl1b (NM_199217) was 
constructed using Phylogeny.fr (Dereeper et al., 2008) with mammalian homologous 
proteins sorted by performing alignment on UniProtKB/Swiss-Prot database.  
 
2.3.3 Reverse transcription quantitative real-time polymerase chain reaction 
Total RNA was extracted using the Trizol Reagent (Invitrogen). cDNA synthesis was 
performed using Superscript III First-strand Synthesis System (Invitrogen). PCR was 
conducted using iTaq Universal SYBR Green Supermix in triplicate (Bio-Rad). 
Optimized primers targeting each gene were designed using Primer3 (Untergasser et al., 
2012). The StepONE Plus PCR System (Applied Biosystems) was used to obtain the Ct 
value. The relative gene expression of each sample was determined using the 
comparative Ct method with β-actin as an internal control (Schmittgen and Livak, 2008). 
The following primers were used: fhl1b: forward 5’-
GTGAGGAAAGACGAGAAACAAG-3’, reverse 5’-GGCACATCGGAAACAATCAG-




2.3.4 Embryo microinjection 
Knockdown of fhl1b was performed via injection of individual fhl1b MO 1 (2 ng; 5’-
CCCGCGAAAAGCTGTGAGAAATAAT-3’) or MO 2 (2 ng; 5’-
ATAAATATCTGTCCCCTCACCTGGC-3’) or a combination of MO1 and 2 (4 ng; 
Gene Tools, LLC). A standard control MO (4 ng; 5’-
CCTCTTACCTCAGTTACAATTTATA-3’) targeting a human beta-globin intron 
mutation was used as a negative control (Gene Tools, LLC). id2a MO (5’ -
GCCTTCATGTTGACAGCAGGATTTC-3’) (Uribe and Gross, 2010) and tp53 MO (5’- 
GACCTCCTCTCCACTAAACTACGAT-3’) (Robu et al., 2007)were purchased from 
Gene Tools, LLC. 4 ng of id2a MO or 2 ng of tp53 MO was used.  The primers annealing 
to the first (5’- GCAAAACACTTTGCTGTGGC-3’) and the sixth (5’- 
GCCAGGTTGAGGGAGCATTT-3’) coding exons were used to confirm the specificity 
of fhl1b MOs. Sense-strand-capped fhl1b-P2A-mCherry mRNA was synthesized with 
mMESSAGE mMACHINE kit (Ambion). For rescue experiments, embryos were 
injected with 200 pg of fhl1b-P2A-mCherry mRNA with a mixture of fhl1b MO 1 and 2. 
 
2.3.5 In situ hybridization and immunohistochemistry 
Whole-mount in situ hybridization was performed as previously described (Alexander et 
al., 1998), using the following probes: pdx1 (Biemar et al., 2001), neurod (Korzh et al., 
1998), hhex (Ho et al., 1999), and fhl1b (template for antisense RNA probe was amplified 
from embryonic cDNA with the following primers: forward: 5’-
CCGCTCGAGATGGCAAGCCGGTCCAACTG-3’, reverse: 5’-
ACGGCTGGTCCTGGTAATTC-3’). Immunohistochemistry on whole-mount embryos 
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was performed as previously described (Dong et al., 2007) using the following 
antibodies: mouse anti-Glucagon (1:100; Sigma), mouse anti-2F11 (1:200; Abcam), 
mouse anti--catenin (1:100; BD Transduction Laboratories), rabbit anti-FHL1 (1:200; 
Abcam), chicken anti-GFP (1:1000; Aves Labs), rabbit anti-Somatostatin (1:100; MP 
Biomedicals), mouse anti-Islet1/2 (1:10; Developmental Studies Hybridoma Bank 
(DSHB), clone 39.4D5), guinea pig anti-Insulin (1:100; Sigma), rabbit anti-Prox1 (1:100; 
Millipore), guinea pig anti-Pdx1 (1:200; gift from C. Wright), rabbit anti-pan-Cadherin 
(1:1000; Sigma), goat anti-Fluorescein (1:100; Molecular Probes), and fluorescently 
conjugated Alexa antibodies (1:200; Molecular Probes). Nuclei were visualized with 
TOPRO (1:10000; Molecular Probes). For the TUNEL assay, embryos were fixed in 3% 
formaldehyde, preincubated in PBST, and then labeled with the TUNEL kit (Roche) for 1 
hour at 37°C. For coimmunostaining with Prox1, sections were first incubated with 
primary antibodies, then with TUNEL solutions, and finally with secondary antibodies. 
Embryos were mounted in Vectashield (Vector Laboratories) and imaged on a Zeiss LSM 
510 VIS confocal microscope.  
 
2.3.6 fhl1b gene disruption with the CRISPR/Cas9 system 
The guide RNA (gRNA) targeting sites, which are downstream of the start codon (gRNA 
1: 5’- CTGTCGTGAGGACCTCAG-3’, gRNA 2: 5’- AGTGGAAAGAAGTTCGTG-3’), 
were selected using the online application available at crispr.mit.edu. Complementary 
oligonucleotides corresponding to the target sequences were annealed as previously 
described (Jao et al., 2013). 1 μl of the annealed oligonucleotides was mixed with 500 ng 
of the gRNA cloning vector pDR274, 0.5 μl of BsaI-HF, 0.5 μl of T4 DNA ligase, 1 μl of 
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10× NEB buffer 2, 1 μl of 10× T4 ligase buffer, and water for a total of 10 μl. Digestion 
and ligation were performed in a single step as previously described (Jao et al., 2013). 
The gRNAs were transcribed using HindIII-digested expression vectors as templates and 
the MEGAshorscript T7 kit (Life Technologies). The cas9 mRNA was transcribed using 
NotI-digested Cas9 expression vector and the mMESSAGE mMACHINE kit (Ambion). 
The mixture of 1 nl of cas9 mRNA (300-450 ng/μl) and an individual or a combination of 
gRNA 1 and 2 (final concentration 12.5 ng/μl) were injected into one-cell stage embryos. 
 
2.3.7 T7 Endonuclease I (T7EI) assay 
The genomic region flanking the target sites was amplified using PCR (forward: 5’-
ACTTACACATGAGGGGCTGTG-3’, reverse: 5’- 
ATAGTCCTTAATGGAAAACATGCTG-3’). A total of 200 ng of the purified PCR 
products was denatured and re-annealed, as previously described (Jao et al., 2013) to 
facilitate heteroduplex formation. The re-annealed products were digested with 10 units 
of T7 endonuclease I (New England Biolabs) at 37°C for 30 min. The reaction was 
stopped by adding 1 μl of 0.5 M EDTA. Samples were analyzed by 2% agarose gel. Band 
intensity was quantified using ImageJ software (National Institutes of Health). Gene 
modification levels were estimated based on the following equation: 
 % (Reyon et al., 
2012). 
 
  1/ 2%    100  1 –  1 –   gene modification fraction cleaved 
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2.3.8 DNA sequencing 
For sequencing the target region in injected embryos, the PCR products were cloned into 
pGEM T-easy vector (Promega). Plasmid DNA was isolated from individual 
transformants and sequenced. 
 
2.3.9 Chemical treatment and heat-shock experiment 
Embryos were treated with 0.3 μM DMH1 (EMD Chemicals) from 12 hpf to 20 hpf or 3 
μM SU 5402 (Tocris Bioscience) from 50 hpf to 72 hpf in egg water. To ablate β-cells, 
Tg(ins:CFP-NTR)s892 embryos were treated with freshly prepared 5 mM metronidazole 
(Mtz) (Sigma) from 84 hpf to 108 hpf in the dark, followed by 36-48 hours recovery. 
Before ablation, Tg(ins:Kaede)-expressing β-cells were converted from green to red by 
exposing them to UV light. Control embryos from the same batch were treated with 
DMSO in egg water. Tg(hsp:fhl1b; hsp:GFP)gt3 and Tg(hsp70l:bmp2b)f13 embryos were 
heat shocked at various stages by transferring them into egg water pre-warmed at 40°C 
and 37°C, respectively. After a 30-minute heat shock, embryos were returned into a 28°C 
incubator and harvested at various stages. 
 
2.3.10 Lineage tracing 
Tg(sox17:GFP)s870 embryos were injected with 2nl of 0.5% caged fluorescein dextran 
and allowed to develop until the 6-somite stage (corresponding to 12 hours-post-
fertilization (hpf)). After manual dechorionation, embryos were mounted ventrally in a 
mold filled with egg water. Using a Nikon Eclipse Ti confocal microscope, we visualized 
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the endodermal sheet in live embryos at the 6-8 somite stage, and the A-P position of 
endodermal cells was determined by counting somites. Caged-fluorescein was activated 
in a single endodermal cell in each embryo with a 405 nm laser focused through a 40X 
objective lens. The uncaged embryos were fixed at various time points and stained with 
antibodies against GFP, the uncaged-Fluorescein, and Islet1 or Prox1. 
 
2.3.11 Glucose measurements  
Glucose measurements were performed on 3 times on 10 zebrafish larvae per condition 
using a fluorescence-based enzymatic detection kit (Biovision Inc.) (Andersson et al., 
2012). The larvae were collected in 1.5 ml microcentrifuge tubes. Excess medium was 
removed and embryos were frozen on crushed dry ice. After thawing, 200μl PBS was 
added and the larvae were homogenized using a hand-held mechanical homogenizer. 
Reactions were assembled on ice in black, flat bottom 96-well plates (Costar). Standard 
curves were generated using glucose standard solution (according to instructions) and 
were included in each assay. To measure glucose in embryo extracts, 15 ul of sample 
were used. Control reactions without sample lysate were included in each row. Reactions 
were incubated for 30 minutes at 37°C in the dark. Fluorescence (excitation 535 nm; 
emission, 590 nm) was measured using a Safire II plate reader equipped with XFLUOR4 
software (v 4.51).  
Fluorescence values were corrected by subtracting measurements from control reactions 
without sample. Glucose levels were interpolated from standard curves. Each sample was 
measured in triplicate and each experiment repeated three times.  
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2.3.12 Statistical analysis 
The p-values were calculated using an unpaired two-tailed Student t-test with 















2.4.1 fhl1b is a target of the Bmp2b pathway 
To discover new Bmp2b downstream target genes potentially regulate the fate 
decision of bipotential hepatopancreatic progenitors, hence to facilitate unveiling the 
mechanism underneath, we performed microarray analyses on zebrafish endodermal cells 
exposed to increased or decreased Bmp signaling, before and during the organogenesis of 
liver and pancreas. The transgenic zebrafish line Tg(sox17:GFP)s870 labels all endodermal 
cell population with green fluorescent protein (GFP) (Chung and Stainier, 2008), 
enabling us to use fluorescence activated cell sorting (FACS) to exclusively collect them 
for analysis. For expression profiling of samples experienced enhanced Bmp2b signaling, 
zebrafish embryos were obtained from crossing Tg(sox17:GFP)s870 line with a heat-shock 
inducible bmp2b overexpressing transgenic zebrafish line, to precisely induce Bmp2b 
signaling before the fate decision of bipotential progenitor cells occurs. For expression 
profiling of samples with reduced Bmp signaling, embryos were obtained from 
Tg(sox17:GFP)s870 line, and treated with DMH1 (a highly selective inhibitor of the BMP 
type I receptors Alk3 (Bmpr1a) and Alk8 (Acvr1/Alk2)) (Hao et al., 2010), to decrease 
the level of Bmp2b signaling during fate decision. Endodermal cells from these treated 
embryos were dissociated and sorted. Total RNA was extracted from them and prepared 






Figure 2.1 Scheme for the preparation of performing expression profiling to identify 
Bmp2b downstream genes. 
Levels of Bmp2b signaling was pharmacologically or genetically manipulated in 
Tg(sox17:GFP)s870 embryos either by treating with DMH1 or inducing bmp2b expression 
at the 8-somite stage. Tg(sox17:GFP)s870-positive endodermal cells from dissected 
zebrafish trunks containing the organ-forming area (red rectangle) were isolated by 












Genes identified by the profiling analysis with the cutline of 2-fold (in the case of 
increased Bmp2b signaling) or 2.75-fold (in the case of decreased Bmp2b signaling) 
changes (p ≤ 0.05) were clustered by biological processes, using Gene Ontology analysis 
by PANTHER program (http://www.pantherdb.org/). A total of 998 genes showed 
changes in increased Bmp2b signaling, and 1261 genes showed changes in decreased 
Bmp2b signaling, respectively. To find out genes that are direct downstream targets of 
Bmp2b signaling, we grouped genes that exhibited a change in expression in both 
conditions (Figure 2.2A). 56 genes met this criterion. Among them, four and a half LIM 
domains 1b (fhl1b), had a prominent change in expression (Figure 2.2B).  
To confirm the microarray results of fhl1b, the mRNA transcription levels of 
fhl1b was assessed by reverse transcription quantitative real-time polymerase chain 
reaction (RT-qPCR), in embryos overexpressing bmp2b or treated with DMH1 (Figure 
2.3A). To dissect the initiation developmental stage and level of fhl1b expression, total 
RNAs of variously staged embryos were extracted and reversed transcribed, then 
amplified by reduced-cycle PCR, using fhl1b primers and β-actin primers as internal 
control. Based on PCR results, the endogenous transcription of fhl1b starts around the 12-







Figure 2.2 Strategy for the identification of Bmp2b downstream genes potentially 
associated with the liver versus pancreas fate decision. 
(A) Functional clustering and distribution of known genes identified in the expression 
profiling with a p-value ≤ 0.05 and minimum a 2-fold change in bmp2b overexpressing or 
a 2.75-fold change in DMH1-treated embryos. 56 known genes showed significant 
changes in both bmp2b overexpressing and DMH1-treated embryos. (B) List of 









                   
Figure 2.3 Confirmation of fhl1b expression from microarray results 
(A) Quantitative real-time PCR analysis of fhl1b in bmp2b-overexpressing or DMH1-
treated embryos at 20 hpf. fhl1b expression levels were normalized to the levels of β-
actin and presented as fold changes (mean±SD) against control expression. Asterisks 
indicate statistical significance: ***, P < 0.001. (B) fhl1b full-length transcript starts to be 











To investigate temporal and spatial expression pattern of fhl1b in the developing 
endodermal tissues, we performed double antibody and in situ hybridization staining. At 
24 hours-post-fertilization (hpf), fhl1b is primarily expressed in the anterior part of the 
endoderm, which corresponds to the prospective liver region, (Figure 2.4A-B, black 
arrows). When combined with GFP staining in Tg(sox17:GFP)s870 embryos, the 
colocalization of in situ signal and GFP indicated that fhl1b is highly expressed in the 
endodermal tissues developing into liver (Figure 2.4E-E’, black arrows; early-forming 
dorsal pancreatic bud, which develops into principal islet, containing endocrine 
pancreatic cells, is marked by dotted circles). Besides endodermal tissues, fhl1b expresses 
in the pronephric duct (Figure 2.4A and 2.4C, blue arrowheads) and heart (Figure 2.4A 
and 2.4C-D, black arrowheads) from 24 hpf onwards. At 30 hpf, levels of fhl1b 
expression maintain high in the liver (Figure 2.4C-D, and 2.3F, black arrows) when the 
liver is budding out from the medially migrated endodermal rod (Field et al., 2003b). 
TgBAC(neurod:EGFP)nl1 line marks pancreatic endocrine progenitors with EGFP. At 78 
hpf, levels of fhl1b expression stay high in the differentiated liver (Figure 2.4G, black 
arrow). Levels of fhl1b expression are also high in patches of cells in the distal intestine 
(Figure 2.4G), low in the HPD system (Figure 2.4G, black bracket), and absent in most of 
the pancreatic cells except for a few cells in the periphery of the principal islet (Figure 
2.4G, yellow arrow; figure 2.4G’-G”, insets showing magnified views of fhl1b expression 




             
Figure 2.4 The expression pattern of fhl1b during early development. 
(A-B) Whole-mount in situ hybridization showing the expression of fhl1b at 24 hpf. fhl1b 
is expressed in the anterior part of the endoderm, which corresponds to the prospective 
liver region (black arrows). Additionally, fhl1b is expressed in the pronephric duct (blue 
arrowhead) and heart (black arrowhead). (C-D) Whole-mount in situ hybridization 
showing the expression of fhl1b at 30 hpf. fhl1b continues to be highly expressed in the 
liver (black arrows) when the liver has started budding from the medially migrated 
endodermal rod. fhl1b also remains to be expressed in the pronephric duct (blue 
arrowhead) and heart (black arrowheads). (E-E’) Double antibody and in situ 
hybridization staining of fhl1b at 24 hpf in Tg(sox17:GFP)s870 embryos. fhl1b is primarily 
expressed in the anterior part of the endoderm, which corresponds to the prospective liver 
anlage (black arrows). Black dotted circles point out the dorsal pancreatic bud. (F-G”) 
Double antibody and in situ hybridization staining of fhl1b in TgBAC(neurod:EGFP)nl1 
embryos at 30 (F) and 78 (G) hpf. TgBAC(neurod:EGFP)nl1 expression marks the 
posteriorly located pancreatic endocrine cells. At 78 hpf, the level of fhl1b expression is 
high in the liver (black arrow) and in patches of cells in the distal intestine, low in the 
HPD system (black bracket), and absent in most of the pancreatic cells (G). Magnified 
images for fhl1b and TgBAC(neurod:EGFP)nl1expression in the principal islet are shown 
in insets. In the principal islet, fhl1b expression is confined to the peripheral boundary 
and does not significantly overlap with the TgBAC(neurod:EGFP)nl1 expression. 
Asterisks indicate statistical significance: ***, P < 0.001. E-G”, confocal single-plane 
images combined with the projection images showing Tg(sox17:GFP)s870 (E-E’) and  
TgBAC(neurod:EGFP)nl1 expression (F-G”), ventral views, anterior to the top. A and C, 
lateral views, anterior to the left. B and D, dorsal views, anterior to the left. n=10 per each 
time point and condition. Scale bars, 20 µm. 
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To confirm that Bmp2b signaling activates fhl1b, we checked the patterns and 
levels of fhl1b expression, in the excess or absence of Bmp2b signaling. Compared to 
control embryos (Figure 2.5A, black bracket; Figure 2.5D), embryos exposed to 
excessive levels of bmp2b, which was induced before the initiation of endogenous bmp2b 
expression, exhibited a drastic expansion of fhl1b expression (Figure 2.5B, black bracket; 
Figure 2.5D). On the other hand, embryos experienced decreased levels of Bmp signaling 
with DMH1 treatment showed a significant reduction of fhl1b expression, particularly in 
the liver at 30 hpf (Figure 2.5C, black bracket; Figure 2.5D). These results reassured that 













Figure 2.5 fhl1b is a target of the Bmp2b pathway. 
(A-C) Double antibody and in situ hybridization staining showing the endogenous 
expression of fhl1b in the liver (black brackets), comparing control (A), bmp2b-
overexpressing (B), and DMH1-treated (C) TgBAC(neurod:EGFP)nl1 embryos at 30 hpf. 
fhl1b expression was greatly expanded when bmp2b expression was induced at the 8-
somite stage (B), but was dramatically reduced in DMH1-treated embryos (C). (D) 
Quantification of the fhl1b-positive in situ hybridization signal at 30 hpf. The areas of 
fhl1b-positive signal were selected and measured using Image J with normalization to 
control. 3 individual embryos were analyzed for each condition. Asterisks indicate 
statistical significance: ***, P < 0.001. A-C, confocal single-plane images combined with 
the projection images showing TgBAC(neurod:EGFP)nl1 expression (A-C), ventral views, 












To find the mammalian orthologs of fhl1b, we searched and compared the four 
and a half LIM domains proteins in mouse, rat, and human, and determined their 
evolutionary relationships. Based on the phylogenetic tree of zebrafish Fhl1b and the 
related proteins in mammals, Fhl1 was selected as the mouse ortholog of zebrafish Fhl1b 
(Figure 2.6A). Next we checked if the expression pattern of zebrafish fhl1b is conserved 
across species. Mouse Fhl1 shares 61% amino acid identity with zebrafish Fhl1b (Figure 
2.6B).  
We investigated mRNA and protein expression patterns of Fhl1 in developing 
mouse embryos. At embryonic day 8.5-9.5 (E8.5-9.5), Fhl1 mRNA is detected in the 
foregut endoderm where the liver and the pancreas are derived (Wandzioch and Zaret, 
2009) (Figure 2.7A). From E10.5 onwards, Fhl1 is expressed in the liver (Figure 2.7A). 
At E14.5, Fhl1 proteins are highly expressed in the Prox1-positive liver cells (Figure 
2.7B-B’’’), whereas their expression is weakly detected in the Prox1-positive pancreatic 
cells (Sosa-Pineda et al., 2000; Wang et al., 2005) (Figure 2.7C-C’’’). These findings 
suggest that similar to the expression pattern of zebrafish fhl1b, mouse Fhl1 is primarily 
expressed in the developing liver. Taken together, these results indicate that the 





Figure 2.6 Fhl1 is the mouse ortholog of zebrafish fhl1b. 
(A) Phylogenetic tree of zebrafish Fhl1b (highlighted in blue) and the related proteins in 
mammals. This tree was constructed using Phylogeny.fr with sorted candidates from 
UniProtKB/Swiss-Prot database. Zebrafish (dr), Mouse (mm), Rat (rn), and Human (hs). 
(B) Alignment of zebrafish Fhl1b and mouse Fhl1 amino acid sequences. Identical 




Figure 2.7 Fhl1 is consistently expressed in the liver during mouse embryonic 
development. 
(A-C’’’) Expression of Fhl1 in the developing mouse embryos. (A) Fhl1 full-length 
transcript is expressed in the mouse foregut endoderm at embryonic day 8.5-9.5 (E8.5-
9.5). From E10.5, Fhl1 is consistently expressed in the liver. (B-C’’’) Immunofluorescent 
labeling of Fhl1 in the liver (B-B’’’) and pancreas (C-C’’’) of E14.5 mice (n=3). (B-B’’’) 
Fhl1 proteins are highly co-expressed in the Prox1-positive liver cells. (C-C’’’) Fhl1b 
proteins are weakly detected in the Prox1-positive pancreas cells. To better visualize 
hepatic and pancreatic Fhl1 expression, magnified images for Prox1 (red; top panel), Fhl1 
(green; middle panel), and a merged view (bottom panel) are shown in insets in B’-B’’’ 









2.4.2 Loss-of-function and gain-of-function studies of fhl1b 
2.4.2.1 Loss of fhl1b promotes pancreatic cells specification and compromises liver 
specification 
To investigate the function of Fhl1b, especially during the process of endodermal 
progenitor fate decision, we disrupted the editing of fhl1b mRNA, hence reduce the levels 
of functional Fhl1b, with morpholino oligonucleotides (MOs). We tested two MOs, one 
(MO1) is against the splice acceptor site of the second exon, which includes the start 
codon; the other (MO2) is against the splice donor site of the third exon (Figure 2.6A). 
To validate the knockdown specificities and efficiency of fhl1b MOs, total RNA of MO-
injected embryos was extracted, reverse transcribed, and PCR amplified with primers 
flanking the full-length coding sequence of fhl1b (Figure 2.8A). MO 1 and 2 successfully 
blocked the endogenous splice sites of fhl1b. A deletion of exon 2 (MO 1; Figure 2.8B, 
white asterisk) or a formation of a cryptic splice form of exon 3 (MO 2; Figure 2.8B, 
white asterisk) was detected. When a mixture of both MO 1 and 2 was injected, it led to 
the deletion of both exon 2 and 3 (MO 1 & 2; Figure 2.8B, white asterisk).  
To check whether loss of fhl1b could result in the alteration of liver versus 
pancreas fate decision, shown as a phenotype of Bmp2b signaling suppression (Chung et 
al., 2010; Chung et al., 2008), we injected Tg(ins:GFP)zf5 embryos, in which all β-cells 
are labeled by GFP, with either single MO 1 or MO 2 as well as a mixture of MO 1 and 
2. At 55 hpf, we examined the expression domain of GFP-positive cells in the pancreas 
and Prox1-positive cells in the liver using antibody staining, to score the change of sizes 
of these two organs. MO-injected embryos (morphants) showed reduced liver size and 
increased β-cell population (Figure 2.8C).  To achieve high MO knockdown efficiency 
with low injection dose, throughout this study, fhl1b MOs were used as a mixture of MO 
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1 and 2 (2 ng of each) since each MO caused essentially the same phenotype (Figure 
2.8C), and standard control MO was used as a negative control. 
 
 
Figure 2.8 Specificity of fhl1b morpholinos. 
(A) Schematic diagram of fhl1b genomic structure and targeting positions of fhl1b MOs 
(red lines). Black arrows indicate the position of primers (F and R) used for PCR 
amplification shown in (B). E1-E6: exon 1 to exon 6. Dark grey, coding regions; Light 
grey, untranslated regions. (B) RT-PCR analysis of fhl1b knockdown efficiency. Both 
MO 1 and MO 2 blocked the endogenous splice site of fhl1b and. As shown, a deletion of 
exon 2 (MO 1, white asterisk) or a formation of a cryptic splice form of exon 3 (MO 2, 
white asterisk) was detected, while a combination of MO 1 and 2 led to deletion of both 
exon 2 and 3 (MO 1 & 2, white asterisk). (C) The percentages of embryos are given for 
each single MO or combination of MOs based upon the expression domain of 
Tg(ins:GFP)zf5 in the pancreas and Prox1 in the liver at 55 hpf. The embryos were scored 
as having a “reduced” or “increased” expression domain when the expression area of 
each marker was distinctly (> 25%) smaller or larger than that of the control embryos 
based upon the calculation using ImageJ. 
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Next we performed more detailed phenotypic analysis on fhl1b morphants. At 30 
hpf, morphants showed a decrease of the hhex (Ober et al., 2006) expression domain in 
the liver (Figure 2.9A-B, black arrows), whereas its expression appeared to be expanded 
in the early-forming dorsal pancreatic bud, which gives rise exclusively to the principal 
islet, a cluster of endocrine cells (Figure 2.9A-B, white dotted circles). The pdx1 
expression domain in morphants was also expanded in the dorsal pancreatic bud (Figure 
2.9C-D, white dotted circles), whereas its expression in the intestinal bulb primordium 
appeared to be reduced (Figure 2.9C-D, black brackets).  
Immunostaining with the antibodies recognizing Pdx1 and the early liver marker 
Prospero homeobox protein 1 (Prox1; (Field et al., 2003b)) in Tg(sox17:GFP)s870 
embryos (Chung and Stainier, 2008) (Figure 2.10A-B’) as well as Islet and Prox1 in 
Tg(ins:GFP)zf5 embryos ((Huang et al., 2001), Figure 2.10C-D’), respectively, showed an 
evident reduction of the Prox1 expression domain in the liver (Figure 2.10A-D’), an 
increase in the number of Tg(ins:GFP)zf5-expressing and Islet-positive pancreatic 
endocrine cells (Figure 2.10C-D’, white dotted circles), and an expansion of the Pdx1-
expressing cell population in the dorsal pancreatic bud in morphants at 30-36 hpf (Figure 
2.10A-B’, white dotted circles). The Pdx1 expression domain in the intestinal 
primordium appeared to be decreased in morphants (Figure 2.10A-B’, yellow brackets). 
At 55 hpf, morphants continuously exhibited an enlarged Insulin-expressing β-cell 
population (Figure 2.10E-G; 33.9±2.1 cells in controls vs. 57.8±3.6 cells in morphants; 
n=5 per condition; P=0.00003) with a reduced number of Prox1-positive cells in the liver 
(Figure 2.10E-G; 262.7±14.0 cells in controls vs. 148.0±15.2 cells in morphants; n=5 per 
condition; P=0.00003).  
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Figure 2.9 Loss of fhl1b activity expands expression of pancreatic gene domain and 
compromises expression of liver gene domain. 
(A-D) Whole-mount in situ hybridization showing the expression of hhex (A and B) and 
pdx1 (C and D), comparing control embryos (A and C) and fhl1b morphants (B and D) at 
30 hpf. hhex is expressed in the liver (black arrows) and the dorsal pancreatic bud (white 
dotted circles). pdx1 is expressed in the developing pancreas including the dorsal 
pancreatic bud (white dotted circles) and intestine (black brackets), but not in the liver. 
hhex expression was reduced in the liver of fhl1b morphants, while expanded in the 
dorsal pancreatic bud (B). pdx1 expression in the dorsal pancreatic bud was also 
expanded, while its expression in the intestinal bulb primordium appeared to be reduced 
in fhl1b morphants (D) compared to that of control embryos (C). A-D, dorsal views, 
anterior to the left.  
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Figure 2.8 Loss of fhl1b activity enhances induction of pancreatic cells and 
compromises liver specification. 
(A–B′) Confocal images of control embryos (A and A′) and fhl1b morphants (B and B′) 
at 30 hpf, stained for Pdx1 (red; expression in the dorsal pancreatic bud is outlined by 
white dotted circles) and Prox1 (blue). The somites are also Pdx1 positive. Compared to 
that of control embryos (A and A′), in fhl1b morphants (B and B′), the Pdx1 expression 
domain in the dorsal pancreatic bud was expanded, while the Prox1 expression domain 
was reduced. Note that the Pdx1 expression domain in the intestinal primordium (yellow 
brackets) appeared to be decreased in morphants (B’). (C-D’) Confocal images of 
Tg(ins:GFP)zf5 control embryos (C and C′) and fhl1b morphants (D and D’) at 36 hpf, 
stained for Islet (red; expression in the dorsal pancreatic bud is outlined by white dotted 
circles) and Prox1 (blue in C and D; grey in C’ and D’). In fhl1b morphants (D and D’), 
the Prox1expression domain was greatly reduced, whereas the number of Tg(ins:GFP)zf5- 
and Islet-expressing cells was increased. (E and F) Confocal images of 
Tg(sox17:GFP)s870 control embryos (E) and fhl1b morphants (F) at 55 hpf, stained for 
Insulin (red; outlined by white dotted circles) and Prox1 (blue). fhl1b morphants (F) 
continuously exhibited an enlarged Insulin-expressing β-cell population with a reduced 
number of Prox1-positive cells in the liver. (G) Quantification of the number (mean±SD) 
of Insulin-positive cells in the pancreas (red) and Prox1-positive cells in the liver (blue) at 
55 hpf. Cells in 20 planes of confocal images from 5 individual larvae were counted. 
Asterisks indicate statistical significance: ***, P < 0.001. A-F, confocal projection 
images, ventral views, anterior to the top. Scale bars, 20 µm. 
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MO-mediated knockdown can often induce apoptosis mediated via aberrant p53 
activation. Hence, we performed simultaneous knockdown of tp53 and fhl1b to 
ameliorate apoptosis induced by MO off-targeting (Robu et al., 2007). We did not detect 
any differences in the phenotype of a small liver between single fhl1b (Figure 2.11B; 
white dotted circles) and double fhl1b/tp53 MO-injected larvae (Figure 2.11C; white 
dotted circles) at 55 hpf. Consistently, no obvious difference in the phenotype of the 
increased Insulin-expressing β-cell population as well as pericardial edema between 
single fhl1b (Figure 2.11E; white squares and insets) and double fhl1b/tp53 MO-injected 
larvae (Figure 2.11F; white squares and insets) at 5 dpf was detected.  
Similarly, the reduced Prox1-expressing cell population in single fhl1b morphants 
(Figure 2.12B) was persistent to that in embryos co-injected with fhl1b and tp53 MOs 
(Figure 2.12C). These data indicate that fhl1b knockdown phenotypes in the endoderm 
and heart are independent of the p53 pathway. 
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Figure 2.9 Loss of Fhl1b activity phenotypes are not caused by p53 induced 
apoptosis. 
(A-C) Fluorescent images of Tg(ins:dsRed)m1018 and Tg(sox17:GFP)s870 expression 
showing that the developmental defects of the liver (white dotted circles) and β-cell 
formation in single fhl1b morphants (B) was comparable to double fhl1b/tp53 morphants 
(C) at 55 hpf (n = 52, control; n = 64, single fhl1b morphants; n = 72, double fhl1b/tp53 
morphants). (D-F) Bright-field images combined with fluorescent images showing the 
overall morphology of embryos and Tg(ins:dsRed)m1018 expression (red) in control (D), 
single fhl1b morphants (E), and double fhl1b/tp53 morphants (F) at 5 dpf. The enlarged 
Tg(ins:dsRed)m1018-expressing cell population (white squares and insets) in single fhl1b 
morphants (E) was similar to that in embryos co-injected with fhl1b and tp53 MOs (F). 
Note that potential off-target ventricle lumen inflation defects in the brain of single fhl1b 
morphants were attenuated by co-knockdown of tp53 (black arrows), whereas pericardial 
edema persisted both in single fhl1b morphants and double fhl1b/tp53 morphants (black 
arrowheads). (G) Quantification of the results in D-F. The embryos were scored as 
having an “increased” expression domain when the expression area of Tg(ins: dsRed)m1018 
was distinctly (> 25%) larger than that of the control embryos based upon the calculation 
using ImageJ. A-C, dorsal views, anterior to the left. D-F, lateral views, anterior to the 
right. I-K, confocal projection images, ventral views, anterior to the top. Scale bars: A-C 
and I-K, 20 μm; D-F, 100 μm. 
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Figure 2.10 The reduced liver cell number in fhl1b depletion is not caused by p53 
induced apoptosis. 
(A-C) Confocal images of control embryos (A), single fhl1b morphants (B), and double 
fhl1b/tp53 morphants (C) at 55 hpf, stained for Prox1 (blue). The reduced Prox1-
expressing cell population in single fhl1b morphants (B) was similar to that in embryos 
co-injected with fhl1b and tp53 MOs (C). (D) Quantification of the number (mean±SD) 
of Prox1-positive cells in the liver at 55 hpf. 252.6±11.5 cells were Prox1-positive in 
control embryos, while 151.3±16.2 and 142.3±17.4 cells expressed Prox1 in single fhl1b 
morphants and double fhl1b/tp53 morphants, respectively (P = 0.0009 and P = 0007, 
respectively). Cells in 20 planes of confocal images from 5 individual embryos were 
counted. Asterisks indicate statistical significance: ***, P < 0.001. A-C, confocal 





In addition, no TUNEL-positive liver cells were observed in fhl1b morphants at 
48 hpf, suggesting that the small liver observed in morphants was not caused by 






Figure 2.11 Cell death does not contribute to the reduction of liver size upon fhl1b 
depletion. 
(A-B) TUNEL labeling (red) combined with anti-Prox1 immunostaining (grey) revealed 
that no TUNEL-positive liver cells were observed both in fhl1b morphants and control 
embryos at 48 hpf. (C-C’) As a control, Tg(fabp10a:CFP-NTR)gt1 embryos were used. 
Treating metronidazole (MTZ) caused apoptosis in a large number of hepatocytes. A-C’, 
confocal projection images, ventral views, anterior to the top. Scale bar, 20 µm. 
 43 
To furthermore confirm that fhl1b MO specifically targets the endogenous fhl1b 
mRNA editing, we co-injected in vitro transcribed fhl1b-P2A-mcherry mRNA with fhl1b 
MO. Co-injection of fhl1b mRNA with a mixture of MO 1 and 2 successfully rescued the 
effect of fhl1b MO knockdown (Figure 2.14A-C’’). 
 
Figure 2.12 fhl1b mRNA injection rescues the effect of fhl1b MO knockdown. 
(A-C’’) The developmental defects of the liver (A-C and white dotted circles in A”-C”) 
and β-cell formation (A-C and A’-C’) in fhl1b morphants (B-B’’) could be rescued by 
injection of fhl1b-P2A-mcherry mRNA (C-C’’), restoring liver size and the β-cell 
population to a degree comparable to that of control embryos (A-A’’) at 55 hpf. Fhl1b 
translation was monitored by mCherry expression as shown in C. (D) Quantification of 
the results in A-C’’. The embryos were scored as having a “reduced” or “increased” 
expression domain when the expression area of Tg(ins:dsRed)m1018 and 
Tg(sox17:GFP)s870 was distinctly (> 25%) smaller or larger than that of the control 
embryos based upon the calculation using ImageJ. A-C, bright-field images combined 
with fluorescent images. A’-C’’, fluorescent images. Dorsal views, anterior to the left. 
Scale bar, 20 µm. 
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To complement fhl1b MO knockdown studies, knockout of fhl1b was performed 
by applying the CRISPR/Cas9 nuclease targeting system (Hwang et al., 2013), which has 
been shown to lead to highly efficient biallelic conversion in somatic cells in zebrafish 
(Jao et al., 2013). We microinjected cas9 mRNA and two guide RNAs (gRNAs), which 
were both designed to target overlapping regions in the exon 2 of fhl1b (Figure 2.15A), 
into one-cell stage embryos. We found that 11.62% of Cas9/gRNA-treated embryos (38 
out of 327 embryos) showed an enlarged Insulin-expressing β-cell population (31.6±3.51 
cells in controls vs. 45.3±6.0 cells in Cas9/gRNA-treated embryos; n=5 per condition; 
P=0.02) with a reduced number of Prox1-positive cells in the liver (265±18.6 cells in 
controls vs. 164±16.5 cells in Cas9/gRNA-treated embryos; n=5 per condition; P=0.002) 
as in fhl1b MO knockdown embryos at 55 hpf (Figure 2.15D-F). We randomly selected 4 
embryos with these phenotypes and confirmed to contain insertions/deletions (indels) 
with the T7 endonuclease I (T7EI) assay and Sanger sequencing. T7EI assay revealed 
that the percent gene modification in the 4 tested embryos was between 21.75% and 
31.58% (Figure 2.15B). Sanger sequencing of these 4 embryos (20-30 PCR amplicons 
were sequenced for each embryo) confirmed site-specific insertions/deletions (indels) 
including 2-17 bp deletions or 2-11 bp insertions (Figure 2.15C). Consistent with the 
report that Cas9 cuts the target DNA at six base pairs upstream of the protospacer 
adjacent motif (PAM) (Jinek et al., 2012), all mutations occurred at the 3′ end of the 
target sequence, further validating the sequence specificity of this targeting process. 
Taken together, these comparable MO knockdown and CRISPR/Cas9 knockout results 
suggest that Fhl1b is required for restraining endodermal progenitors from specifying to 
pancreatic endocrine cells and for the proper induction of the liver. 
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Figure 2.13 Cas9/gRNAs induces indels in the fhl1b locus in zebrafish. 
(A) Illustration showing the position of each gRNA-targeting site in the fhl1b locus in 
zebrafish. Black arrows indicate the position of primers (F and R) used for sequencing to 
identify indels shown in (C). (B) Representative T7 assay showing the efficiency of 
Cas9-mediated cleavage in a single embryo at 55 hpf.  (C) Representative Sanger 
sequencing results of the PCR amplicons of 4 individual embryos at 55 hpf, showing 
indels induced by Cas9/gRNA in the targeted fhl1b locus. Twenty to thirty clones were 
sequenced for each embryo. The wild-type sequence is shown at the top with the target 
sites highlighted in yellow and the PAM sequences (TGG and AGG) highlighted in blue. 
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Deletions are shown as red dashed lines and insertions are highlighted in red. The net 
change in length caused by each indel is to the right of each sequence (+, insertion; -, 
deletion). (D-E’) Confocal images of Tg(ins:GFP)zf5 control embryos (D and D’) and 
Cas9/gRNA-induced mutant embryos (E and E’) at 55 hpf, stained for Prox1 (blue in D 
and E; grey in D’ and E’) and Islet (red; expression in the dorsal pancreatic bud is 
outlined by white dotted circles). Cas9/gRNA-induced mutant embryos exhibited an 
enlarged Insulin-expressing β-cell population with a reduced number of Prox1-positive 
cells in the liver, phenocopying that of the fhl1b MO knockdown embryos. (F) 
Quantification of the number (mean±SD) of Insulin-positive cells in the pancreas (green) 
and Prox1-positive cells in the liver (blue) at 55 hpf. 31.6±3.5 cells were Insulin-positive 
in control embryos, whereas 45.3±6.0 cells expressed Insulin in Cas9/gRNA-induced 
mutant embryos. 164±16.5 cells expressed Prox1 in Cas9/gRNA-induced mutant 
embryos, while 265±18.6 cells were Prox1-positive in control embryos. Cells in 20 
planes of confocal images from 5 individual larvae were counted. Asterisks indicate 
statistical significance: *, P < 0.05, **, P < 0.01. D-E’, confocal projection images, 





2.4.2.2 Decreased fhl1b activity augments induction of pancreatic endocrine cells 
The To further analyze which pancreatic cell types are induced in fhl1b 
morphants, we first examined the expression of Tg(P0-pax6b:GFP)ulg515, a pan-endocrine 
progenitor reporter (Delporte et al., 2008). The number of Tg(P0-pax6b:GFP)ulg515-
expressing cells increased from 82.6±4.5 in controls to 103.2±2.0 in morphants at 30 hpf 
(Figure 2.16A-B, and 2.16I; n=5 per condition; P=0.0009). Next, we investigated which 
endocrine subpopulation was expanded in the morphants. The number of Insulin-
expressing β-cells (Huang et al., 2001) was increased from 30.6±1.5 in controls to 
44.6±2.0 in morphants at 30 hpf (Figure 2.16C-D, and 2.16I; n=5 per condition; 
P=0.0004). While the number of Somatostatin-expressing δ-cells was also increased in 
morphants (Figure 2.16E-F, and 2.16I; 20.7±0.8 cells in controls vs. 26.7±2.0 cells in 
morphants; n=5 per condition; P=0.0033), the number of Glucagon-expressing α-cells 
was slightly decreased in morphants (Figure 2.16G-H, and 2.16I; 26.5±0.7 cells in 
controls vs. 23.0±1.0 cells in morphants; n=5 per condition; P=0.02). As recently 
reported (Ye et al., 2015), Insulin and Glucagon, but not Insulin and Somatostatin, are co-
expressed in both control embryos and fhl1b morphants at 30 hpf. The number of these 
dual-hormone expressing cells was decreased in fhl1b morphants at 30 hpf (10.0±1.4 




Figure 2.14 Decreased fhl1b activity augments induction of pancreatic endocrine 
cells. 
(A-H) Confocal images showing Tg(P0-pax6b:GFP)ulg515 (A and B, green), Insulin (C 
and D, red), Somatostatin (E and F, grey), and Glucagon (G and H, blue) expression at 30 
hpf, comparing control embryos (A, C, E, and G) and fhl1b morphants (B, D, F, and H). 
The number of Tg(P0-pax6b:GFP) (B)- and Insulin (D)-expressing cells was significantly 
increased in fhl1b morphants compared to that of control embryos (A and C, 
respectively). The number of Somatostatin-expressing cells was also increased (F), while 
that of Glucagon-expressing cells appeared slightly decreased in fhl1b morphants (H) 
compared to that of control embryos (E and G, respectively). (I) Quantification of the 
number (mean±SD) of total and individual pancreatic endocrine hormone-expressing 
cells, comparing that of control embryos and fhl1b morphants at 30 hpf. Cells in 20 
planes of confocal images from 5 individual larvae were counted. Asterisks indicate 
statistical significance: **, P < 0.01; ***, P < 0.001. 
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A previous report showed that cell-autonomous suppression of Bmp signaling is 
critical for the induction of endocrine cells derived not only from the early-forming 
dorsal bud but also from the late-forming ventral bud (Chung et al., 2010). In zebrafish, 
the late-forming ventral pancreas, which mostly generates pancreatic exocrine cells 
(acinar and duct cells) as well as endocrine cells, subsequently encapsulates the early-
forming dorsal pancreas, which gives rise exclusively to the endocrine cells and is also 
pdx1-positive, to establish the mature pancreatic structure (Field et al., 2003a). To test the 
role of Fhl1b in the induction of endocrine cells from the ventral bud specifically, we 
examined the numbers of the newly differentiated ventral bud-derived endocrine cells in 
Tg(ins:GFP)zf5;Tg(ins:dsRed)m1018 double transgenic embryos. As dsRed takes 18-22 
hours longer than GFP to mature, we can distinguish GFP only (ventral bud-derived) 
from GFP/dsRed double-positive (dorsal bud-derived) β-cells until at least 60 hpf 
(Hesselson et al., 2009). At 48 hpf, the number of GFP-only-positive β-cells increased in 
morphants compared to that of control embryos (Figure 2.17A-C; 5.0±0.7 cells in 
controls vs. 12.2±2.3 cells in morphants; n=5 per condition; P=0.0002), suggesting an 




Figure 2.15 Decreased fhl1b activity augments induction of both dorsal and ventral 
insulin cells. 
(A-B’) Confocal images of Tg(ins:GFP)zf5;Tg(ins:dsRed)m1018 control embryos (A and 
A’) and fhl1b morphants (B and B’) at 48 hpf. Compared with the control embryos (A), 
fhl1b morphants showed an increased number of GFP-only-positive β-cells (B, white 
arrows). (C) Quantification of the number (mean±SD) of GFP- and dsRed-double 
positive (yellow) and GFP-only-positive (green) β-cells, comparing that of control 
embryos and fhl1b morphants at 48 hpf. 5.0±0.7 β-cells were GFP-only-positive in 
control embryos, while 12.2±2.3 β-cells were GFP-only-positive in fhl1b morphants. 
Cells in 20 planes of confocal images from 5 individual larvae were counted. Asterisks 
indicate statistical significance: ***, P < 0.001. Scale bars, 20 µm. 
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We further quantified total and subpopulations of pancreatic endocrine cells at 72 
hpf. The number of Tg(P0-pax6b:GFP)ulg515-, Insulin-, and Somatostatin-expressing cells 
was increased from 98.6±3.0, 32.3±2.0, and 28.7±1.4, respectively, in control embryos, 
to 132.0±5.2, 54.8±3.5, and 40.0±2.1, respectively, in morphants (Figure 2.18A-G; n=5 
per condition; P=0.0003, P=0.0003, P=0.006, respectively), while the number of 
Glucagon-expressing cells was slightly decreased (Figure 2.18C, and 2.18F; 30.0±2.0 
cells in controls vs. 25.3±2.0 cells in morphants; n=5 per condition; P=0.04). Altogether, 
these data suggest that Fhl1b is required for restricting the induction of pancreatic 






Figure 2.16 Decreased fhl1b activity increases the number of pancreatic endocrine 
cells. 
(A-F) Confocal images showing Tg(ins:dsRed)m1018 (A and D) or Insulin (B-C, E-F, red) 
expression with Tg(P0-pax6b:GFP)ulg515 (A and D, green), Somatostatin (B and E, grey), 
or Glucagon (C and F, blue) expression at 72 hpf, comparing control embryos (A-C) and 
fhl1b morphants (D-F). The number of Tg(ins:dsRed)m1018- or Insulin-expressing cells 
was significantly increased in fhl1b morphants (D-F) compared to that of control embryos 
(A-C). The number of Tg(P0-pax6b:GFP)- and Somatostatin-expressing cells was also 
increased (D and E, respectively), whereas that of Tg(gcga:GFP)ia1-expressing cells 
appeared slightly decreased (F) in fhl1b morphants compared to control embryos (A, B, 
and C, respectively). A-F, confocal projection images, ventral views, anterior to the top. 








2.4.2.3 Increased fhl1b activity suppresses specification of pancreatic cells and 
induces liver 
In a converse experiment, we assessed the effects of ectopic expression of fhl1b 
on liver and pancreas induction. We overexpressed fhl1b using a heat-inducible 
transgene, Tg(hsp:fhl1b; hsp:GFP)gt3. In response to heat shock, robust ectopic 
expression of GFP was observed in a variety of tissues throughout the embryos without 
any discernible body phenotype. Concurrent expression of fhl1b all over the embryos was 
confirmed with whole-mount in situ hybridization. When fhl1b expression was induced at 
the 8-somite stage, the initial time point of pdx1 expression in the pancreatic exocrine and 
intestinal progenitors and before the beginning of endogenous fhl1b expression, hhex 
expression domain was greatly expanded in the liver at 45 hpf (Figure 2.19A-B, black 
arrows). In these embryos, pdx1 expression was significantly reduced in the intestinal 
bulb primordium and ventral pancreas, which gives rise mainly to the pancreatic exocrine 
cells, intestine cells, and a few endocrine cells (Fig 2.19C-D, black brackets). pdx1 
expression in the dorsal pancreatic bud appeared unaffected (Figure 2.19C-D, white 
dotted circles), consistent with the previous data that the lineage of this bud is specified 





Figure 2.17 Ectopic Fhl1b induces the expression of liver gene domain and 
suppresses the expression of pdx1 domain. 
(A-D) Whole-mount in situ hybridization showing the expression of hhex (A and B) and 
pdx1 (C and D), comparing control embryos (A and C) and fhl1b-overexpressing 
embryos (B and D, heat shock applied at the 8-somite stage). hhex is expressed in the 
liver (black arrows) and the dorsal pancreatic bud (white dotted circles). pdx1 is 
expressed in the developing pancreas including the dorsal pancreatic bud (white dotted 
circles) and intestine (black brackets), but not in the liver. When fhl1b expression was 
induced at the 8-somite stage, hhex expression was greatly expanded in the liver (B, black 
arrow), while pdx1 expression in the developing gut was reduced (D, black bracket). hhex 
and pdx1 expression in the dorsal pancreatic bud in fhl1b-overexpressing embryos was 














To determine whether specification of pancreatic exocrine cells is affected in 
fhl1b-overexpressing embryos, we examined the expression of Tg(ptf1a:GFP)jh1 
(Godinho et al., 2005), which is largely restricted to the developing exocrine pancreas 
(Wang et al., 2015c), along with Prox1, which is highly expressed in the liver and 
developing exocrine pancreas at 50 hpf. Compared to control embryos, we found that in 
the embryos where fhl1b expression was induced at the 8-somite stage, 
Tg(ptf1a:GFP)jh1expression was almost completely eliminated whereas the Prox1 
expression domain was markedly expanded, suggesting that virtually all Prox1-
expressing cells are liver cells (Figure 2.20A-B’). Quantification showed that while 
235.5±7.3 cells were Prox1-positive in control embryos, 306.5±12.6 cells expressed 
Prox1 in fhl1b-overexpressing embryos (Figure 2.20C; n=5 per condition; P=0.000067). 
In contrast, the number of Tg(ptf1a:GFP)jh1-expressing cells was decreased from 
82.2±6.4 in controls to 16.0±5.2 in fhl1b-overexpressing embryos (Figure 2.20D; n=5 per 
condition; P=0.000004). These results suggest that Fhl1b is sufficient to inhibit 












Figure 2.18 Ectopic Fhl1b suppresses specification of pancreatic cells and induces 
liver. 
(A-B’) Confocal images showing Islet (red), Prox1 (blue in A and B; grey in A’ and B’), 
and Tg(ptf1a:GFP)jh1 (green) expression at 50 hpf, comparing control embryos (A and 
A’) and fhl1b-overexpressing embryos (B and B’, heat shock applied at the 8-somite 
stage). When fhl1b expression was induced at the 8-somite stage (B and B’), the Prox1 
expression domain was expanded, whereas Tg(ptf1a:GFP)jh1 expression was drastically 
reduced. (C) Quantification of the number (mean±SD) of Prox1-positive cells in the liver 
at 50 hpf. 235.5±7.3 cells were Prox1-positive in control embryos, while 306.5±12.6 cells 
were Prox1-positive in fhl1b-overexpressing embryos (heat shock applied at the 8-somite 
stage). (D) Quantification of the number (mean±SD) of Tg(ptf1a:GFP)jh1-expressing cells 
in the exocrine pancreas at 50 hpf. The number of these cells decreased from 82.2±6.4 in 
control embryos to 16.0±5.2 in fhl1b-overexpressing embryos (heat shock applied at the 
8-somite stage). Cells in 20 planes of confocal images from 5 individual larvae were 
counted. Asterisks indicate statistical significance: ***, P < 0.001. A and B, confocal 
projection images; A’ and B’, confocal single-plane images, ventral views, anterior to the 





2.4.3  Fhl1b as a major effector of Bmp signaling determines the fate of the 
endodermal progenitors into liver versus pancreas   
2.4.3.1 Fhl1b regulates the patterning and subsequent fate of the medial and lateral 
endodermal progenitors 
To determine the role of Fhl1b in the M-L patterning of endodermal progenitors, 
which is essential for the fate decision of liver versus pancreas (Chung et al., 2008), we 
first examined the pdx1 gradient in the endodermal sheet of fhl1b-depleted embryos. 
From the 14-somite stage onwards, morphants showed a dramatic lateral expansion of the 
pdx1 expression domain (Figure 2.21A-B). The expression domain of neurod, which 
marks pancreatic endocrine progenitor cells that express high levels of pdx1 
(corresponding to the cells with white asterisks in Figure 2.21A-B; (Chung et al., 2008; 
Soyer et al., 2010)), was markedly expanded (Figure 2.21C-D). Furthermore, multiple 
TgBAC(neurod:EGFP)nl1-expressing cells were found even in the lateral part of the 
endodermal sheet, which normally gives rise to the liver, exocrine pancreas, and intestine 




Figure 2.19 Fhl1b regulates the patterning of the medial and lateral endodermal 
progenitors. 
(A-D) Whole-mount in situ hybridization showing the expression of pdx1 (A and B) and 
neurod (C and D), comparing that of control embryos (A and C) and fhl1b morphants (B 
and D) at the 14-somite stage (A and B) and 18 hpf (C and D). pdx1 is expressed at high 
levels in the most medial cells (white asterisks) and at low levels in the lateral cells 
(white arrows). neurod is expressed in the high-level pdx1-expressing cells. In fhl1b 
morphants, high levels of pdx1 (white asterisks) and neurod expression were expanded 
laterally (B and D). (E-F) Ventral confocal images showing TgBAC(neurod:EGFP)nl1, β-
catenin (white), and Topro (blue) at 18 hpf (the notochord is outlined by yellow dashed 
lines). Somites are numbered from anterior to posterior (S1-S4). (E) In control embryos, 
TgBAC(neurod:EGFP)nl1-expressing cells are located close to the notochord. (F) Ectopic 
TgBAC(neurod:EGFP)nl1-expressing cells were found in lateral endodermal regions in 
fhl1b morphants (white arrows).  
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 Next, we performed single-cell lineage tracing experiments to examine possible 
cell fate changes caused by modulation of fhl1b activity. Tg(sox17:GFP)s870 embryos 
were injected at the one-cell stage with the photoactivatable lineage tracer CMNB-caged 
fluorescein dextran conjugate, and single endodermal cells at 3 different M-L positions  
(medial, lateral 1, and lateral 2) at the level of somite 2 were uncaged using a 405nm 
laser at the 6–8 somite stage. In Consistent with earlier data (Chung et al., 2008), in 
control embryos, lateral 2 cells at the level of somite 2 predominantly gave rise to the 
exocrine pancreas, intestine, and liver, but rarely to the endocrine pancreas (Figure 2.22A 
and 2.26C-E, 2.26F (as L2), 2.26H; in 1 out of 10 control embryos lateral 2 cells gave 
rise to the endocrine pancreas). In every fhl1b-depleted embryo, lateral 2 cells contributed 
to the pancreatic endocrine cells (Figure 2.22B and 2.26D, 2.26F (as fhl1b MO L2), 








                      
Figure 2.20 Fhl1b regulates the fate of the medial and lateral endodermal 
progenitors. 
(A and B) Confocal images of Tg(sox17:GFP)s870 embryos at 55 hpf, stained for 
uncaged-Fluorescein (red) and Islet (blue). In control embryos (A), lateral 2 (L2) cells 
gave rise to the liver (white rhombi), intestine (white arrowhead), and exocrine pancreas 
(white double arrows), but rarely gave rise to the endocrine pancreas. In fhl1b morphants 
(B), L2 cells contributed to the Islet-positive pancreatic endocrine cells (white arrows), 
but not to the liver or exocrine pancreas. 
 
 
Assessment of exocrine pancreas development and differentiation by analyzing 
the expression of Tg(ptf1a:GFP)jh1, which labels developing exocrine pancreatic cells, as 
well as that of Tg(fabp10a:DsRed;ela3l:EGFP)gz15 (Farooq et al., 2008), which marks 
differentiated hepatocytes and pancreatic acinar cells, showed a reduced number of 
pancreatic exocrine cells at 72 and 96 hpf (Figure 2.23A-D). These data suggest that 
depletion of Fhl1b function results in the conversion from no/low to high pdx1-
expressing cells, leading to a significant increase in the number of pancreatic endocrine 
cells along with a concomitant compromise of the development of liver and pancreatic 




Figure 2.21 Decreased fhl1b activity inhibits liver and exocrine pancreas 
differentiation. 
(A and B) Confocal images of Tg(ptf1a:GFP)jh1 control embryos (A) and fhl1b 
morphants (B), stained for Prox1 (grey). The expression domain of the Prox1 and 
Tg(ptf1a:GFP)jh1 was reduced in fhl1b morphants (B) compared to that of control 
embryos (A). (C and D) Confocal images of Tg(fabp10a:RFP, ela3l:EGFP)gz12 control 
embryos (C) and fhl1b MO-injected larvae (D) at 96 hpf. The expression domain of the 
Tg(fabp10a:RFP, ela3l:EGFP)gz12 was reduced both in the liver and exocrine pancreas in 
fhl1b MO-injected larvae (D) compared to that of control larvae (C). A-D, confocal 







Conversely, we examined the pdx1 gradient in fhl1b-overexpressing embryos. In 
Tg(hsp:fhl1b; hsp:GFP)gt3 embryos in which fhl1b expression was induced at the 8-
somite stage, medial cells, as their counterpart in control embryos, exhibited high levels 
of pdx1 (Figure 2.24A-B, white asterisks). Consistently, neurod expression appeared 
unaffected (Figure 2.24C-D). In contrast, lateral cells exhibited greatly reduced levels of 
pdx1 compared to that of control embryos (Figure 2.24A-B, white arrows), demonstrating 
that fhl1b overexpression during the post-gastrulation stage led to a decrease of pdx1 
expression in the pancreatic exocrine and intestinal progenitors.  
Next, a single lateral 1 cell in Tg(hsp:fhl1b; hsp:GFP)gt3 embryos was heat- 
shocked and uncaged at the 6-8 somite stage. In every embryo where fhl1b expression 
was induced at the 6-8 somite stage, lateral 1 cells contributed to the liver (Figure 2.25B 
and 2.26D, 2.26G (as HS @ 8s L1), 2.26H; n=11); However, in most control embryos 
lateral 1 cells only gave rise to the pancreas and intestine, but not to the liver (Figure 
2.25A and 2.26B, 2.26D-E, 2.26G (as L1), 2.26H; 1 out of 10 control embryos showed 
contribution of lateral 1 cells to the liver). These results indicate that augmentation of 
Fhl1b activity decreases pdx1 expression levels in pancreatic exocrine and intestinal 




Figure 2.22 Fhl1b regulates the patterning of the medial and lateral endodermal 
progenitors. 
(A-D) Whole-mount in situ hybridization showing the expression of pdx1 (A and B) and 
neurod (C and D) at 18 hpf, comparing control embryos (A and C) and fhl1b-
overexpressing embryos (B and D, heat shock applied at the 8-somite stage). In embryos 
induced to overexpress fhl1b at the 8-somite stage (B and D), neurod and high levels of 
pdx1 expression (white asterisks in B) were maintained, while low levels of pdx1 






                       
Figure 2.23 Fhl1b regulates the fate of the medial and lateral endodermal 
progenitors. 
(A-B’) Confocal images of Tg(sox17:GFP)s870 embryos at 50 hpf, stained for uncaged-
Fluorescein (red) and Prox1 (blue in A and B; grey in A’ and B’). In control embryos (A 
and A’), lateral 1 (L1) cells gave rise to the exocrine pancreas (white double arrows) and 
the intestine (white arrowheads), but not to the liver. In embryos induced to overexpress 
fhl1b at the 8-somite stage (B and B’), L1 cells mostly contributed to the Prox1-positive 
liver cells (white rhombi). Scale bars, 20 µm. 
 
As previously reported (Chung et al., 2008), the medial cells at the 6-8 somite 
stage, which express high levels of pdx1, give rise mostly to pancreatic endocrine cells 
(Figure 2.26A, 2.26D-E, 2.26H; n=11), indicating an early fate restriction of these cells 
primarily during the gastrulation stage. Taken together, these results suggest that Fhl1b 
plays an essential role in determining the precise patterning of medial and lateral 
endodermal progenitors by modulating the levels of pdx1 expression for proper fate 




Figure 2.24 Endodermal progenitors contribute to distinct endodermal tissues based 
on their M-L position and the activity of fhl1b. 
(A-C) Confocal images of Tg(sox17:GFP)s870 embryos at 55 hpf, stained for Islet (blue) 
and uncaged-Fluorescein (red), showing the progeny of the medial (A), lateral 1 (B) and 
lateral 2 (C) cells. Medial cells (A) mostly gave rise to pancreatic endocrine cells (white 
arrows). Lateral 1 cells (B) gave rise to pancreatic exocrine (white double arrows), 
endocrine (white arrow), and intestinal (white arrowheads) cells. Lateral 2 cells (C) gave 
rise to liver (white rhombi), intestine (white arrowhead), and pancreatic exocrine cells 
(white double arrow). (D-H) The numbers and the percentages of embryos that showed 
incorporation into a given tissue type in each specific position, comparing control 
embryos (D, E, F (as L2), G (as L1), and H) as well as fhl1b morphants and embryos 
induced to overexpress fhl1b at the 8-somite stage (D, F (as fhl1b MO L2), G (as HS @ 
8s L1), and H). In every fhl1b-depleted embryo, lateral 2 cells contributed to the 
pancreatic endocrine cells (D, F (as fhl1b MO L2), and H), while in control embryos, 
most of the lateral 2 cells gave rise to the exocrine pancreas, intestine, and liver, but 
seldom gave rise to the endocrine pancreas (D, E, F (as L2), and H). In control embryos, 
lateral 1 cells mostly gave rise to pancreatic and intestinal cells, but not to liver cells (D, 
E, G (as L1), and H), whereas in every fhl1b-overexpressing embryo, lateral 1 cells 
contributed to the liver (D, G (as HS @ 8s L1), and H). Data in each 3-D column (%) in 
E-G were obtained by summing the number of embryos that showed incorporation into a 
given tissue type and normalizing it to the total number of embryos examined in each 
specific position: M, L1 and L2. Colored rectangles in H highlight the most dominant 
pattern in fhl1b morphants (red) and fhl1b-overexpressing (blue) embryos. A-C, confocal 








2.4.3.2 Relationship between Bmp2b, Fhl1b, and Id2a in fate choice of liver versus 
pancreas 
Our data indicate that Fhl1b is a novel physiological effector of Bmp2b signaling 
that regulates the adequate fate choice for liver and pancreas. To investigate the epistatic 
relationship between Bmp2b signaling and Fhl1b, we induced bmp2b expression at the 8-
somite stage in the presence or absence of fhl1b. As previously reported (Chung et al., 
2008), in bmp2b-overexpressing embryos, the Prox1 expression domain in the liver was 
significantly expanded (Figure 2.27B), whereas the number of Islet-positive pancreatic 
endocrine cells appeared unaffected (red; dorsal pancreatic bud is outlined by white 
dotted circle; Figure 2.27B). We found that the majority of bmp2b-overexpressing fhl1b 
morphants exhibited an enlarged Islet-positive pancreatic endocrine cell population (red; 
dorsal pancreatic bud is outlined by white dotted circle; Figure 2.27D, 80%) with a 
reduced number of Prox1-positive cells in the liver (Figure 2.27D, 80%) as in fhl1b 
morphants (Figure 2.27C), whereas a small portion of bmp2b-overexpressing fhl1b 
morphants restored the developmental defects of the liver and pancreatic endocrine 
formation (Figure 2.27D, 20%). These results suggest that Fhl1b is a critical mediator of 





Figure 2.25 Fhl1b is an essential mediator of Bmp2b signaling directing liver versus 
pancreas fate decision. 
(A-D) Confocal images of control embryos (A), bmp2b-overexpressing embryos (B), 
fhl1b morphants (C), and bmp2b-overexpressing fhl1b morphants (D) at 72hpf, stained 
for Islet (red; expression in the dorsal pancreatic bud is outlined by white dotted circles) 
and Prox1 (blue). (B) Prox1 expression in the liver was greatly expanded when bmp2b 
expression was induced at the 8-somite stage, whereas Islet expression in the 
mesenchymal cells surrounding the HPD system as well as in the pancreatic endocrine 
cells appeared unaffected. As in fhl1b morphants (C), the majority of bmp2b-
overexpressing fhl1b morphants exhibited an enlarged Islet-positive pancreatic endocrine 
cell population with a reduced number of Prox1-positive cells in the liver (D, 80% (22 
out of total 28 embryos analyzed)). A small portion of bmp2b-overexpressing fhl1b 
morphants restored the developmental defects of the liver and pancreatic endocrine 
formation (D, 20% (6 out of total 28 embryos analyzed)). A-D, confocal projection 












Furthermore, these data raise the possibility of other effector(s) of Bmp2b 
signaling that may act in concert with Fhl1b in this process. Hence, we analyzed the 
function of Id2, which has been implied in suppressing the function of Neurod (Hua et 
al., 2006) and an immediate target of Bmp signaling (Miyazono and Miyazawa, 2002). 
Zebrafish have two id2 genes: id2a and id2b (Khaliq et al., 2015). Only id2a is 
restrictively expressed in the liver from 30 hpf onwards (Khaliq et al., 2015). We 
conducted loss-of-function analyses using published id2a MO (Uribe and Gross, 2010). 
While id2a morphants showed a decrease of the hhex expression domain in the liver 
(Figure 2.28B, black arrow), its expression in the dorsal pancreas appeared unaffected at 
30 hpf (Figure 2.28B, white dotted circle). Consistently, the pdx1 expression domain in 
id2a morphants was comparable to that of control embryos (Figure 2.28F). Double 
id2a/fhl1b morphants exhibited synergistically more severe defects in liver formation 
(Figure 2.28D, black arrow) than that of single id2a (Figure 2.28B, black arrow) or single 
fhl1b morphants (Figure 2.28C, black arrow), whereas the dorsal pancreas of double 
morphants (Figure 2.28D and 2.28H, white dotted circles) phenocopied that of single 
fhl1b morphants (Figure 2.28C and 2.28G, white dotted circles). The expression of id2a 
in fhl1b morphants in the liver biliary epithelial cells was comparable to that of control 
embryos at 72 hpf (Figure 2.28I-J). Taken together, these data indicate that Fhl1b is an 
essential mediator of Bmp2b signaling in determining the proper fate decision of liver 
versus. pancreas. These results further suggest that an unknown effector of Bmp2b 
signaling may play a role in regulating this process, while Id2a is primarily necessary for 
regulating liver development (Figure 2.28K). 
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Figure 2.28 Fhl1b, but not Id2a, is an essential mediator of Bmp2b signaling 
directing liver versus pancreas fate decision. 
(A-H) Whole-mount in situ hybridization showing the expression of hhex (A-D) and pdx1 
(E-H), comparing control embryos (A and E), id2a morphants (B and F), fhl1b morphants 
(C and G), and double fhl1b/id2a morphants (D and H) at 30 hpf. hhex is expressed in the 
liver (black arrows) and the dorsal pancreatic bud (white dotted circles). pdx1 is 
expressed in the developing pancreas including the dorsal pancreatic bud (white dotted 
circles) and intestine (black brackets), but not in the liver. The hhex expression domain 
was reduced in the liver of id2a morphants (B, black arrow) but appeared unaffected in 
the dorsal pancreatic bud (B, white dotted circle). fhl1b morphants showed a reduced 
hhex expression domain in the liver (C, black arrow) with a concomitant expansion of its 
expression domain in the dorsal pancreatic bud (C, white dotted circle). Double 
fhl1b/id2a morphants showed a more severe reduction of hhex expression domain in the 
liver (D, black arrow), whereas its expression domain in the dorsal pancreatic bud was 
comparable to that in single fhl1b morphants (compare C and D, white dotted circles). 
pdx1 expression in id2a morphants was comparable to that in control embryos (F). pdx1 
expression domain in double fhl1b/id2a morphants in the dorsal pancreatic bud was 
expanded (H, white dotted circle), whereas its expression in the intestinal bulb 
primordium appeared to be reduced (H, black bracket), and was comparable to that in 
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fhl1b morphants (G, white dotted circle and black bracket, respectively). (I-J) Whole-
mount in situ hybridization showing the expression of id2a. The expression of id2a in 
fhl1b morphants in the liver biliary epithelial cells (J) was comparable to that in control 
embryos (I) at 72 hpf. (K) Schematic model of the relationship between Bmp2b, Fhl1b, 
and Id2a in liver versus pancreas fate decision. Fhl1b is essentially required for 
suppressing pdx1 expression to keep progenitors competent to differentiate into the liver, 
while Id2a is required primarily for liver development. Solid lines indicate connections 
supported by the data presented in this study, while dashed lines indicate potential 
connections by an unknown effector. A-J, dorsal views, anterior to the left (n=20 per each 




















We identified and analyzed the role of a novel Bmp2b downstream effector Fhl1b 
in the liver versus pancreas fate decision. In bipotential hepatopancreatic progenitors 
from the 12-somite stage onwards, Fhl1b regulates the proper cell fate choice by 
modulating the levels of pdx1 expression (Figure 2.29). The portion of the progenitor 
population that express high pdx1 level mainly differentiate into pancreatic endocrine 
cells, while the portion in which pdx1 expression is suppressed mostly develop into liver 




Figure 2.29 pdx1 levels are associated to the cell fate of progenitors. 
Endodermal progenitors experience different levels of pdx1 regulating their fates as 
pancreatic endocrine (high levels of pdx1), pancreatic exocrine (low levels of pdx1), or 





fhl1b depletion compromised liver specification and enhanced induction of 
pancreatic cells, causing a hepatic-to-pancreatic endocrine fate switch. Conversely, fhl1b 
overexpression promoted liver specification and inhibited induction of pancreatic cells, 
redirecting pancreatic progenitors to become liver cells (Figure 2.30).  
 
 
Figure 2.30 Fhl1b is essential for regulating the cell fate choice of liver versus 
pancreas. 
From the 12-somite stage onwards, single endodermal cells in the lateral 2 position (L2) 
between somites 1 and 3 in the endodermal sheet give rise not only to pancreatic exocrine 
cells and intestinal cells, but also to liver cells, functioning as bipotential 
hepatopancreatic progenitors. bmp2b, which is expressed in the lateral plate mesoderm, 
induces fhl1b expression in the prospective liver anlage. This may form a reciprocal 
gradient of fhl1b-pdx1. Decreased fhl1b function leads to an increase in levels of pdx1 
expression in lateral 1 and 2 cells, causing a hepatic and pancreatic exocrine to a 
pancreatic endocrine fate switch. Conversely, augmentation of fhl1b activity at the initial 
time point of pdx1 expression in the pancreatic exocrine and intestinal progenitors (HS @ 
8 S) causes a decrease in levels of pdx1 expression in pancreatic exocrine and intestinal 
progenitor cells, leading them to become liver cells. The lineage of the most medial cells, 
which express high levels of pdx1 and subsequently give rise to pancreatic endocrine 




Previously, it’s showed that there is a medial-lateral pdx1 “gradient” in the 
endodermal sheet in zebrafish (Chung et al., 2008). The most medial cells with high 
levels of pdx1 mainly gave rise to pancreatic endocrine cells, whereas lateral 1 cells with 
low levels of pdx1 gave rise to pancreatic exocrine cells and intestinal cells, as well as a 
few pancreatic endocrine cells. Some lateral 2 cells without pdx1 expression populate the 
liver. Consistently, in mice, it was suggested that the level of Pdx1 gene activity is 
differentially required for the proper development of the pancreas and subsequent lineage 
allocation of the pancreatic endocrine cells (Fujitani et al., 2006). While homozygous 
mutants of the Pdx1 enhancer region deletion resulted in severe impairment of endocrine 
maturation but normal formation of acinar tissue, heterozygous mice showed an islet size 
similar to that of wild type mice with abnormally more α- and pancreatic polypeptide- 
producing PP cells but fewer differentiated β-cells. These findings support the possibility 
that conversion of common endocrine precursors to β-cells relies on a high-level of Pdx1 
expression. Our studies show that depletion of fhl1b resulted in the conversion from 
no/low to high pdx1-expressing cells, which is marked by neurod expression. This 
conversion led to a significant increase in the number of pancreatic endocrine cells, 
especially β-cells and compromised the development of liver and pancreatic exocrine 
cells, which are derivatives of no and low pdx1-expressing cells. In these embryos, lateral 
2 cells contributed frequently to pancreatic endocrine cells. Conversely, fhl1b 
overexpression at the post-gastrulation stage (i.e. 8-somite stage) caused a decrease in the 
number of low pdx1-expressing cells, leading to the induction of the liver at the expense 
of the exocrine pancreas. In these embryos, lateral 1 cells contributed primarily to liver 
cells. When fhl1b was overexpressed during the gastrulation stage, the number of cells 
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expressing low and high levels of pdx1 decreased with a subsequent decrease in the 
number of pancreatic exocrine cells and Insulin-expressing β-cells, thus, confirming the 
critical role of Fhl1b in the modulation of pdx1 levels to coordinate the medio-lateral 
patterning of the endodermal sheet for proper induction of the liver and pancreas. 
Intriguingly, the numbers of β- and δ-cells were increased, whereas the number of α-cells 
was slightly decreased in fhl1b morphants. These results are consistent with previous data 
that Bmp receptor alk8 MO-injected donor cells mainly gave rise to β- and δ-cells, but 
rarely to α-cells (Chung et al., 2010). It has been shown that β/δ-cell versus α-cell fate is 
differentially regulated by Pax4 and Arx, respectively (Collombat et al., 2003). 
Moreover, overexpression of Pdx1 eliminated glucagon mRNA and protein and promoted 
the expression of β-cell specific genes, while induction of dominant-negative Pdx1 
resulted in differentiation of β-cells into α-cells in the rat insulinoma cell line (Wang et 
al., 2001). Hence, it is plausible to speculate that Fhl1b is an essential mediator of Bmp 
signaling to regulate the discrete levels of pdx1 expression for precise lineage allocation 
of the pancreatic endocrine progenitors. Interestingly, we found that in a portion of 
embryos, fhl1b is also expressed in the TgBAC(neurod:EGFP)nl1-expressing cells. 
Therefore, it is possible to hypothesize that after serving as an essential effector for the 
hepatic versus pancreatic fate decision, Fhl1b may function further to fine-tune the 
lineage allocation of the specified pancreatic endocrine cells. As LIM proteins often 
function as molecular adaptors or scaffolds to support the assembly of multimeric protein 
complexes (Chang et al., 2003), it will be intriguing to determine whether Fhl1b 
modulates pdx1 expression by facilitating the formation of a novel protein complex that 
is involved in either mediator-or chromatin-mediated gene expression control. 
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Our findings of Bmp regulation of Fhl1b suggest a new paradigm of how Bmp 
signaling regulates the cell fate choice of liver versus pancreas and β-cell mass. Despite 
the long-standing focus on the active role of Bmp signaling on the liver gene program 
through both genetic and epigenetic regulation (Rossi et al., 2001; Shin et al., 2007; Xu et 
al., 2011), the link between Fhl1b and pdx1 expression shown in this study suggests that 
Bmp may function actively to suppress the pancreas gene program to properly modulate 
liver induction. Hence, our data elucidates why effective Bmp suppression is critical for 
the induction of PDX1 and the subsequent generation of β-cells from the human 
pluripotent stem cells (Kroon et al., 2008; Nostro et al., 2011; Rezania et al., 2012) and 
from zebrafish endodermal progenitors (Chung et al., 2010). A comprehensive 
understanding of how lineage-specific multipotent progenitors make a developmental 
choice will shed light on the programming and reprogramming of stem/progenitor cells 




CHAPTER 3  
SIGNALING PATHWAYS PROMOTING β-CELL REGENERATION  
 
The work in this chapter contributes to the following publication:  
Xu, J., et al. (2016). PLOS Genetics. 
Xu, J., et al. (2017). Under review. 
 
3.1 Abstract  
Fhl1b as a novel Bmp2b signaling downstream target, regulates regeneration of insulin-
secreting β-cells by modulating pdx1 and neurod expression in the HPD system. Loss of 
fhl1b enhances neogenesis of new β-cells from the progenitor cell population residing in 
the HPD system. While overexpression of fhl1b blocked the endogenous neogenesis of β-
cells during regeneration. In addition, we identified inhibitors of non-canonical IκB 
kinases (IKKs), TANK-binding kinase 1 (TBK1) and IκB kinase ε (IKKε) as enhancers 
of β-cell regeneration. TBK1/IKKε inhibitors stimulated β-cell-specific proliferation. 
TBK1/IKKε inhibitors augmented function and proliferation of β-cells in mammalian 
islets including human islets. TBK1/IKKε inhibitor treatment improved glycemic control 
in streptozotocin (STZ)-induced diabetic mice with increase in β-cell proliferation, and 
total insulin content. Therefore, our work suggests a new paradigm of how Bmp signaling 
regulates β-cell regeneration through its novel target Fhl1b. Our data also shows an 
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evolutionarily conserved and critical role of TBK1/IKKε suppression in expanding 
functional β-cell mass, providing a potential candidate pathway for clinical practice. 
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3.2  Introduction 
It has been reported that -cell regeneration can occur via the proliferation of 
residual -cells (Dor et al., 2004) or the neogenesis of -cells from non--cells (Ye et al., 
2015). Non--cells could be progenitor cells residing in the pancreatic ductal systems 
(Xu et al., 2008) or other mature cell types including glucagon-expressing -cells (Thorel 
et al., 2010). It’s also been suggested that a progenitor cell population in the HPD system 
can be activated and undergo differentiation in later stages. In addition, pdx1 is expressed 
in the HPD system, and may play a role in guiding the fate choice of the progenitors 
(Field et al., 2003a; Kimmel et al., 2011; Spence et al., 2009). Intriguingly, Id2, a Bmp 
signaling marker, is excluded in the endocrine pancreas, and HPD system (Chung et al., 
2010). However, from our expression data, fhl1b, a novel Bmp2b target, is expressed in 
HPD system in later stages. Nonetheless, the underlying mechanisms of how Bmp 
signaling orchestrates the proper lineage choice of the progenitors in the HPD system 
await further investigation. 
Islet inflammation has emerged as a key contributor to the loss of functional -
cell mass in both type 1 diabetes (T1DM) and type 2 diabetes (T2DM) (Esser et al., 2014; 
Imai et al., 2013). In T1DM, -cells are the target of an autoimmune assault. Chronic 
low-grade inflammation and activation of the immune system are major factors in 
obesity-induced insulin resistance and T2DM. Therefore, immunotherapies designed to 
block -cell apoptosis may stand as a unifying target for diabetes treatment. Despite this 
rationale, the slow rate of -cell regeneration in adult humans (Meier et al., 2008; Wang 
et al., 2015b) limits the efficacy of immune-intervention trials. Accordingly, among 
multiple small mitogenic molecules identified (Aamodt et al., 2016; Andersson et al., 
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2012; Annes et al., 2012; Boerner et al., 2015; El Ouaamari et al., 2016; Shen et al., 
2015; Shen et al., 2013; Walpita et al., 2012; Wang et al., 2015a; Wang et al., 2009; Zhao 
et al., 2014), several of them have either not shown or shown minor functional effects in 
human -cells (Andersson et al., 2012; Annes et al., 2012; Boerner et al., 2015; Shen et 
al., 2013; Zhao et al., 2014). Thus, identifying -cell regenerating agents that increase 
residual functional -cells and coupling them with immunomodulators represent an 
auspicious treatment for T1DM and T2DM (Pozzilli et al., 2015).  
Non-canonical IB kinases (IKKs), TANK-binding kinase 1 (TBK1) and IKK, 
have high sequence homology with comparable phosphorylation profiling of substrate(s) 
(Clement et al., 2008). These kinases regulate inflammatory reactions primarily through 
their action on the interferon regulatory factor (IRF) pathway (Caillaud et al., 2005; Chau 
et al., 2008). Upon induction in response to obesity-dependent inflammation, 
TBK1/IKK directly phosphorylate phosphodiesterase (PDE) 3B (Mowers et al., 2013), a 
major cyclic AMP (cAMP) hydrolyzing PDE isoform in adipocytes (Zmuda-
Trzebiatowska et al., 2006). Consequently, genetic deletion of IKKε and pharmacological 
inhibition of TBK1/IKK with amlexanox, a small molecule inhibitor of these kinases, 
increased cAMP levels in adipocytes (Mowers et al., 2013). This led to the secretion of 
interleukin-6 (IL-6) and the activation of the hepatic Signal Transducer and Activator of 
Transcription 3 (STAT3) (Inoue et al., 2004), resulting in reduced gluconeogenesis and 
reversal of metabolic dysfunctions in obese mice (Reilly et al., 2015). In addition, IKK 
was shown to be among putative targets of diarylamide WS6, a small molecule that 
promoted human -cell proliferation in vitro (Boerner et al., 2015; Shen et al., 2013). 
Despite these data suggesting a role for suppression of TBK1/IKK in ameliorating 
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defective glucose handling and in expanding -cells, the key question of how 
TBK1/IKK function in -cells remains elusive. Furthermore, validation of TBK1/IKK 
inhibitors as mitogens for -cells has yet been reported.    
 Intracellular cAMP levels are essential for -cell replication, survival, and 
function (Inada et al., 2004; Xie et al., 2007; Zhao et al., 2014), and they are modulated 
by their rate of synthesis via adenylyl cyclase and their rate of degradation via PDEs 
(Conti and Beavo, 2007). Adenosine receptors A2a and A2b, which are G-protein 
coupled receptors (GPCRs), were shown to increase -cell proliferation during 
homeostatic control and regeneration of the -cell mass by activating Gs and stimulating 
production of cAMP (Andersson et al., 2012; Annes et al., 2012). Several of PDEs 
including PDE3B (Pyne and Furman, 2003) and PDE3A (Byun et al., 2014) are highly 
expressed in -cells. Inhibition of PDE3 with cilostamide was reported to reduce 
streptozotocin (STZ)-induced islet cell death in mice (Byun et al., 2014) and augment -
cell proliferation and regeneration in rat islets and zebrafish (Andersson et al., 2012; 
Zhao et al., 2014), underscoring a critical role of cAMP in -cells.  
Using small molecules in disease treatment has been in favor for several obvious 
advantages. Normally, small molecules are relatively simple and economical for massive 
manufacture. They also remain stable and effective for reasonable periods. Furthermore, 
small molecules are easy to access desired target locations, with or without additional 
delivery carriers. Unlike peptide hormonal factors, which affect a multitude of cellular 
processes and need to be administered by injection, small molecules can be selective and 
taken orally (Vetere et al., 2014). For diabetes treatment, small molecules can be taken 
orally, facilitating to increase residual functional β-cells in patients, or to be applied in 
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vitro to expand β-cell pools in isolated culture from cadaveric donors for transplantation 
(Wang et al., 2015b). Despite all the advantages, specificity and potency are still two of 
the biggest concerns when using small molecules for treatment. So far, multiple small 
mitogenic molecules identified have failed to either show functional effects in human β-
cells or yield reproducible findings (Andersson et al., 2012; Annes et al., 2012; Shen et 
al., 2013; Vetere et al., 2014).  
In this study, using the zebrafish model of type I diabetes, we identified 
TBK1/IKK inhibitors (TBK1/IKK-Is) as enhancers of -cell regeneration. 
Pharmacological and genetic loss- and gain-of-function analyses in zebrafish indicate that 
TBK1/IKK-Is augmented -cell-specific proliferation by increasing cyclic AMP 
(cAMP) levels via PDE3. TBK1/IKK inhibitors improved function and replication of 
mammalian -cells including primary human -cells. Furthermore, TBK1/IKK 
inhibitors improved glycemic control and induced -cell proliferation with increase in 








3.3  Methods 
3.3.1 Zebrafish strains 
To generate the Tg(hsp:pde3a; hsp:GFP)gt4, pde3a coding sequence was amplified 
(forward: 5’- GACGAATTCGTGACCGATGGCACTGGAAT-3’, reverse: 5’- 
GACCTCGAGTCATTCTGGATCTTTCTGGTCTTCG-3’) and cloned into a vector 
containing a multimerized minimal heat shock promoter, which drives gfp and pde3a 
transcription bi-directionally in response to a heat shock (Bajoghli et al., 2004). Tol2-
mediated transgenesis was achieved as described (Kawakami et al., 1998). 
 
3.3.2 Chemical treatment 
The following compounds and the concentrations are used in zebrafish: 100 µM 
amlexanox, 50 µM BX795, 20 µM (E)-3-(3-phenylbenzo[c]isoxazol-5-yl)acrylic acid 
(PIAA), and 20 µM PIAA-1, PIAA-2, and PIAA-3.   
 
3.3.3 Immunohistochemistry 
Immunohistochemistry on whole-mount zebrafish larvae was performed using the 
following antibodies: mouse anti-Glucagon (1:100; Sigma), chicken anti-GFP (1:1000; 
Aves Labs), rabbit anti-Somatostatin (1:100; MP Biomedicals), rabbit anti-Prox1 (1:100; 
GeneTex), and fluorescently conjugated Alexa antibodies (1:200; Molecular Probes). 
Nuclei were visualized with TOPRO (1:10000; Molecular Probes). To assess cell 
proliferation, zebrafish larvae were incubated with 7µM 5-ethynyl-2’-deoxyuridine 
(EdU) and DMSO at 1.7% final concentration for the indicated time period. EdU 
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incorporation was revealed for 30 minutes using Click-iT EdU Imaging Kit (Invitrogen), 
prior to primary antibody staining. Larvae were mounted in Vectashield (Vector 
Laboratories) and imaged on a Zeiss LSM 700-405 confocal microscope. Rabbit anti-
Ki67 (1:100; Abcam) and guinea pig anti-Insulin (1:100; Sigma) antibodies were 
additionally used for immunohistochemistry on rat INS-1 cells, mammalian islet culture, 
and mice pancreata. Nuclei were visualized with TOPRO (1:2000; Molecular Probes). 
Rat INS-1 cells and islet samples were directly imaged in plates on a Zeiss LSM 700-405 
confocal microscope. Mice pancreata were dissected, fixed in 4% PFA, treated with a 
30% sucrose solution, then embedded in Tissue-Tek OCT compound (Sakura Finetek). 8 
μm cryostat sections were obtained by using a cryostat microtome (CryoStar NX70 
Cryostat), stained with antibodies, mounted in Vectashield (Vector Laboratories), and 
imaged on a Zeiss LSM 700-405 confocal microscope. Two 8 µm pancreas sections 
(separated by 400 µm) per mouse were used to assess -cell area. Images were taken after 
Insulin staining using a Zeiss LSM 700-405 confocal microscope, and islet size/area and 
the total areas of the sections were determined using the ZEN software (Zeiss). The 
percentage of -cell area in each section was calculated by dividing the area of all 
insulin-positive cells in one section by the total area of this section. 
  
3.3.4 Glucose and cAMP measurements 
For free glucose measurements, the zebrafish larvae were collected in 2 mL 
microcentrifuge tubes and frozen on crushed dry ice after removal of excess egg water. 
Upon thawing, 200 μL of PBS were added and the larvae were homogenized using a 
hand-held mechanical homogenizer. To measure glucose in larval extracts, 15 μL of 
 85 
supernatant was used and mixed for each reaction, and incubated for 30 minutes at 37°C 
in the dark. Fluorescence (excitation, 535 nm; emission, 590 nm) was measured using 
Biotek Synergy H4 Multi-Mode Plate Reader. Each sample was measured in triplicate. 
For cAMP content measurements, treated zebrafish larvae were collected (10 larvae were 
pooled per condition), homogenized in 100 μL 0.1 M HCl, and centrifuged at 6,000 g for 
10 min at 4°C.  
The rat INS-1 cells were cultured in RPMI 1640 (Gibco) supplemented with 10% FBS, 
1% Penicillin/Streptomycin, 25mM HEPES (Invitrogen), and 50 µM β-mercaptoethanol 
and used for experiments between passages 6-10. INS-1 cells were seeded in 6-well 
plates at 5x105 cells per well and starved for 18 hours in serum-free RPMI with 2.5 mM 
glucose prior to exposure to PIAA for 1 hour. After treatment, cells were lysed in 200 µL 
0.1 M HCl and centrifuged. For mice, 2-3 hours after PIAA  treatment, the relevant 
organs were harvested and homogenized in 0.1 M HCl. Supernatants from all samples 
were collected and stored at −80°C until cAMP content measurements. 
 
3.3.5 Mammalian ex vivo islet culture  
Male Lewis rats were housed on a 12-hour light/dark cycle in a controlled climate 
according to Georgia Institute of Technology regulations. Pancreatic islets were isolated 
from rats by collagenase digestion (Liberase TL, Roche Diagnostics) and gradient 
purification, and then hand-picked and pooled. Islets were cultured overnight in CMRL-
1066 (Invitrogen) supplemented with 10% FBS, 1% Penicillin/Streptomycin, and 25mM 
HEPES (Invitrogen). The next day, islets were either directly treated with PIAA for 4 
days or dissociated with 0.05% trypsin-EDTA (Invitrogen) for 3-5 minutes with gentle 
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agitation to aid cell cluster disruption. Single cells obtained from islet dissociation were 
plated in 96-well plates and allowed 48 hours to attach prior to treatment with PIAA for 4 
days. Human islets were cultured in Human Islet Media (Prodo Labs) supplemented with 
1% Penicillin/Streptomycin and 10% human serum for 24-48 hours prior to 
experimentation.  
 
3.3.6 Glucose tolerance tests 
For glucose tolerance tests, after a twelve-hour fast, mice were given an intraperitoneal 
injection of glucose at a dose of 2 g per kg. We measured blood glucose at basal, 30, 60, 
90, and 120 minutes from tail blood using the OneTouch Ultra glucometer (Lifescan). 
 
3.3.7 Assessment of insulin content 
For insulin content measurements, isolated mice pancreata were placed in acid-ethanol 
mixture (0.18 M HCl, 75% EtOH), incubated overnight (−80°C), and then homogenized; 
the tissue levels of insulin extracted by centrifugation (2,000 rpm, 15 min, 4 °C) were 
then determined by mouse insulin ELISA kit (Mercodia) and normalized to total 
pancreatic protein content determined by Pierce BCA protein assay kit (Thermo Fisher). 
 
3.3.8 Reverse transcription quantitative real-time polymerase chain reaction 
Total RNA was extracted using the Trizol Reagent (Invitrogen). cDNA synthesis was 
performed using ImProm-II Reverse Transcription System (Promega). PCR was 
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conducted using iTaq Universal SYBR Green Supermix in triplicate (Bio-Rad). 
Optimized primers targeting each gene were designed using Primer3 (Untergasser et al., 
2012). The StepONE Plus PCR System (Applied Biosystems) was used to obtain the Ct 
value. The relative gene expression of each sample was determined using the 
comparative Ct method with β-actin or Gapdh as an internal control (Schmittgen and 
Livak, 2008). The following primers were used: mouse Ikbke: forward 5’- 
ACAAGGCCCGAAACAAGAAAT-3’, reverse 5’- ACTGCGAATAGCTTCACGATG -
3’; mouse Tbk1: forward 5’- ACTGGTGATCTCTATGCTGTCA-3’, reverse 5’- 
TTCTGGAAGTCCATACGCATTG-3’; mouse Gapdh: forward 5’- 
TCGTCCCGTAGACAAAATGGT-3’, reverse 5’- TGGCAACAATCTCCACTTTGC-
3’; zebrafish β-actin: forward 5’-CGAGCTGTCTTCCCATCCA-3’, reverse 5’-
TCACCAACGTAGCTGTCTTTCTG-3’; zebrafish ikbke: forward 5’- 
CAGCAAACGTCTACAAAGCCA-3’, reverse 5’- TGAGGAACTCGGACTCAGGA-
3’; zebrafish tbk1: forward 5’- GAAAACAGGCGATCTGTACGC-3’, reverse 5’- 
GCACCTTATGACGTGTGTTCG-3’; zebrafish pde3a: forward 5’- 
TGCTGGAGAATCATCACGCT-3’, reverse 5’- TCATTGGTCCAGTCGATCCC-3’. 
 
3.3.9 Glucose stimulated insulin secretion from ex vivo islet culture 
Human and rat islets were evaluated for glucose stimulated insulin secretion using 
standard methods. Cultured islets with 4-5 days treatment with DMSO or 40-80 
M PIAA were equilibrated within a column in the center of a 1 mL sandwich of 
Sephadex beads using 3 mM glucose in Krebs buffer for one hour. After 
 88 
equilibration, 3-4 replicates per group were subjected to 1 hour sequential 
incubations with Krebs low (3 mM glucose), high (16 mM glucose), and low 
again. Secreted insulin was monitored using a human or rat ELISA kit (Mercodia) 
and normalized to total DNA (PicoGreen, Invitrogen).  
 
3.3.10 Mice experiments 
All mice studied were 6–8-wk old males on the C57BL/6 background (Jackson 
Laboratory). Only mice that had fed blood glucose values of >300 mg glucose/dL were 
used. Mice were given daily intraperitoneal injections of vehicle (dimethylsulphoxide 
final 6.7% formulated in 1% methylcellulose) or PIAA (12.5 mg per kg body weight; 
formulated in 1% methylcellulose). Mice were housed in pathogen-free facilities and 
maintained in the Animal Care Facilities at Parker H. Petit Institute for Bioengineering 
and Bioscience, Atlanta, GA. Studies conducted and protocols used were approved by the 
Institutional Animal Care and Use Committees of Georgia Institute of Technology and 






3.4  Results 
3.4.1 Modulation of fhl1b activity regulates the capacity of β-cell regeneration 
Given the critical role of Fhl1b in restricting the induction of pancreatic endocrine 
cells, we investigated whether altering Fhl1b activity changes β-cell regeneration 
efficiency. Using Tg(ins:CFP-NTR)s892 (Curado et al., 2007) together with 
Tg(ins:Kaede)jh6 (Pisharath et al., 2007), we compared the β-cell regeneration efficiency 
in control vs. fhl1b MO-injected larvae. We first converted the fluorescence of the Kaede 
protein from green to red by exposing the larvae to UV light. This conversion 
permanently marked all β-cells that were present before the ablation step. We then treated 
the larvae from 84−108 hpf with metronidazole (MTZ) to ablate the β-cells. In this set-
up, newly formed β-cells express green-fluorescent Kaede only, whereas β-cells that 
survive the ablation co-express red- and green-fluorescent Kaede. The ablated control 
islets exhibited recovery of green-only β-cells during the washout period (Figure 3.1A, 
3.1C and 3.4A; 3.8±1.3 cells per islet; n=10). In recovering fhl1b MO-injected larvae, we 
observed that a greater number of green-only β-cells regenerated (Figure 3.1B-C and 








Figure 3.1 Reduction of fhl1b activity enhances the capacity of β-cell regeneration. 
(A and B) Confocal images of [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] control larvae 
(A) and fhl1b MO-injected (B) larvae at 36 hours-post-ablation (hpa) stained with Topro 
(blue). A greater number of β-cells regenerated in recovering fhl1b-MO injected larvae 
(B) compared to that of control larvae (A). (C) Quantification of the number (mean±SD) 
of regenerating and surviving β-cells. After photoconversion and ablation, the surviving 
β-cells are red and green (yielding a combined color of yellow), whereas the newly 
formed β-cells are green only. 3.8±1.3 β-cells were green-only-positive in control 
regenerating larvae, while 9.6±1.4 β-cells expressed as green-only in fhl1b-MO injected 
regenerating larvae. Almost no β-cells survived the ablation in both the control and fhl1b-
MO injected regenerating larvae. Cells in 20 planes of confocal images from 10 






Conversely, we overexpressed fhl1b using Tg(hsp:fhl1b; hsp:GFP)gt3 in 
conjunction with Tg(ins:CFP-NTR)s892 and Tg(ins:Kaede)jh6 to measure the regenerative 
efficiency of β-cells in control vs. fhl1b-overexpressing larvae. We found that the number 
of regenerated β-cells significantly decreased when fhl1b was induced at 50 hpf (Figure 
3.4A; 3.8±1.3 cells per islet in control vs. 1.5±0.5 cells per islet in fhl1b-overexpressing 
larvae; n=10 per each condition; P=0.0008). We further examined the underlying 
mechanism of how Fhl1b modulates the efficiency of β-cell regeneration. At 72 hpf, the 
number of Islet-positive cells in or adjacent to the hepatopancreatic ductal (HPD) system 
dramatically decreased after inducing fhl1b at 50 hpf even in the presence of Fgf inhibitor 
SU5402, which induces ectopic Islet1-positive cells in the HPD system (Chung et al., 












Figure 3.2 Fhl1b blocks induction of late-forming ventral bud-derived endocrine 
cells. 
(A-C’) Confocal images of control embryos without SU5402 (A and A’) and with 
SU5402 (B and B’) treatment as well as fhl1b-overexpressing embryos with SU5402 
treatment (C and C’, heat shock applied at 50 hpf) at 72 hpf, stained for Islet (red) and 
Cadherin (blue). Upon treatment of Fgf receptor inhibitor SU5402, ectopic Islet-positive 
endocrine cells appeared in the hepatopancreatic ductal system (HPD) (B and B’, white 
asterisks). This effect was blocked by overexpression of fhl1b (C and C’). The white lines 
depict the junction between the pancreas and the HPD. A-C, confocal projection images; 




Conversely, at 72 hpf, fhl1b morphants showed a dramatic increase of pdx1 and 
neurod expression in the principal islet (Figure 3.3A-B, white dotted circles) and in the 
HPD system (Figure 3.3C-D, white brackets). Intriguingly, fhl1b and pdx1 exhibit a 
reciprocal expression pattern in control embryos at 3 dpf. The level of fhl1b expression is 
high in the liver (Figure 3.3F, black arrow) and in patches of cells in the distal intestine 
(Figure 3.3F, white dotted lines), low in the HPD system (Figure 3.3F, white bracket), 
and absent in most pancreatic cells except for a few cells in the principal islet (Figure 
3.3F, yellow arrow). The pdx1 level of expression is high in the proximal intestine 
(Figure 3.3E, white dotted lines) and in most pancreatic cells, moderate in the HPD 





Figure 3.3 Reduction of fhl1b activity enhances the expression of pdx1 and neurod. 
(A-D) Whole-mount in situ hybridization showing the expression of pdx1 (A and B) and 
neurod (C and D) at 72 hpf, comparing control embryos (A and C) and fhl1b morphants 
(B and D). pdx1 is expressed in the pancreas including the principal islet (white dotted 
circles), the HPD system (white brackets), and the proximal intestine, but not in the liver. 
neurod is expressed mainly in the principal islet (white dotted circles) with slight 
expression in the HPD system (white brackets). pdx1 (B) and neurod (D) expression in 
the principal islet and the HPD system was greatly increased in fhl1b morphants. (E-F) 
Whole-mount in situ hybridization showing the expression of pdx1 (E) and fhl1b (F) in 
wild-type embryos at 3 days-post-fertilization (dpf). (E) pdx1 is expressed in the pancreas 
including the principal islet, the HPD system (white bracket), and the proximal intestine 
(white dotted line), but not in the liver. (F) fhl1b is expressed at high levels in the liver 
cells (black arrow), which never express pdx1, whereas the HPD system (white bracket) 
expresses low levels of fhl1b. Most pancreatic cells except for a few cells in the principal 
islet (yellow arrow) do not express fhl1b. The distal intestine also expresses fhl1b (white 
dotted lines). A-F, dorsal views, anterior to the left.  Scale bars, 20 µm. 
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In line with these expression data, in recovering fhl1b MO-injected larvae, 
multiple regenerating β-cells were found at the junction between the pancreas and the 
HPD system marked with 2F11 (Zhang et al., 2014) (Figure 3.4B-C; white arrowheads). 
 
Figure 3.4 Fhl1b enhances neogenesis of β-cell during regeneration. 
(A) Quantification of the number (mean±SD) of regenerating (Green+) and surviving  
cells (Red+) in control, fhl1b MO-injected, and fhl1b-overexpressing larvae at 36 hours-
post-ablation (hpa). Cells in 20 planes of confocal images from 10 individual larvae were 
counted. (B-C”) Confocal single images and projections of [Tg(ins:CFP-NTR)s892; 
Tg(ins:Kaede)jh6] control (B-B”) and fhl1b MO-injected (C-C”) larvae at 24 hours-post-
ablation (hpa) stained with 2F11 (red) and Carboxypeptidase (blue). A greater number of 
regenerated β-cells in fhl1b-MO injected larvae were mainly located at the junction 
between the pancreas and the HPD system, specifically at the EPD (C-C”). While upper 
insets in B’, B”, C’, and C” show the enlarged images of EPD with white arrows pointing 
the regenerated β-cells, lower insets in B’, B”, C’, and C” only display the magnified 
images of EPD with white arrows. Abbreviations: GB, gallbladder; CBD, common bile 
duct; EHD, extrahepatic duct; EPD, extrapancreatic duct; IHD, intrahepatic duct; IPD, 
intrapancreatic duct. n = 10 per condition. 
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          Double antibody and in situ hybridization staining in Tg(ins:GFP)zf5 embryos at 3 
dpf showed that in the principal islet, fhl1b expression is confined to the peripheral 
boundary and does not overlap with the centrally located β-cells (Figure 3.5A, yellow 
arrow) nor does with the δ-cells (Figure 3.5B, black arrowheads) but partially with a 
small number of α-cells (Figure 3.5C, black arrowheads). 
 
 
Figure 3.5 fhlb expression in the principal islet. 
(A) Double antibody and in situ hybridization staining of fhl1b at 3 dpf in Tg(ins:GFP)zf5 
embryos. At 3 dpf, the level of fhl1b expression is high in the liver (black arrow) and in 
the distal intestine, low in the HPD system (black bracket), and absent in most pancreatic 
cells except for a few cells in the principal islet (yellow arrow). In the principal islet, 
fhl1b expression is confined to the peripheral boundary and does not significantly overlap 
with the core β-cells marked by Tg(ins:GFP)zf5 expression. n = 10. (E-F) Double antibody 
and in situ hybridization staining of fhl1b with Somatostatin (E) and Glucagon (F) at 3 
dpf in Tg(ins:GFP)zf5 embryos. In the principal islet, fhl1b expression (black arrowheads 
in E and F) does not overlap with the Somatostatin-expressing δ-cells (E) but partially 
with a small number of Glucagon-expressing α-cells (F). Tg(ins:GFP)zf5 expression is 
pseudo colored as white, whereas Somatostatin (E) and Glucagon (F) expression is 
outlined by both white and black dotted circles. The relative position of fhl1b-expressing 
cells to the Somatostatin (E) and Glucagon (F) expression are indicated by white (E) and 
yellow (F) arrowheads. Merged views of the middle and right panels are shown in the left 
panels. n = 10 per condition. 
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Previous studies showed that glucose is crucial for β-cell differentiation and 
regeneration (Guillemain et al., 2007; Ye et al., 2015) and acts as a potent β-cell mitogen 
(Alonso et al., 2007; Bonner-Weir et al., 1989; Porat et al., 2011). To test the possibility 
of whether Fhl1b regulates β-cell regeneration by affecting liver-derived glucose 
production, we measured free glucose levels. At 3 dpf, prior to MTZ treatment, there was 
no significant difference in free glucose levels between control/WT, fhl1b-MO injected, 
and fhl1b-overexpressing larvae (Figure 3.6). Free glucose levels were dramatically 
elevated after β-cell ablation, but were recovered to a great extent from 5-7 dpf in MTZ-
treated, MTZ/fhl1b MO-injected, and MTZ/fhl1b-overexpressing larvae (Figure 3.6). 
Importantly, normal levels of free glucose were recovered significantly faster in the 
MTZ/fhl1b MO-injected larvae (Figure 3.6, green line) than in the MTZ-treated (Figure 
3.6, red line) or MTZ/fhl1b-overexpressing larvae (Figure 3.6, purple line). Furthermore, 
MTZ/fhl1b-overexpressing larvae still had increased levels of free glucose at 7 dpf 
(Figure 3.6, purple line) compared to MTZ-treated (Figure 3.6, red line) or MTZ/fhl1b 
MO-injected larvae (Figure 3.6, green line). Taken together, these data suggest that the 
activity of Fhl1b on the HPD system, rather than the liver-derived glucose production, 







Figure 3.6 Fhl1b enhances the restoration of β-cell function. 
Free-glucose levels were measured during β-cell regeneration in wild-type, MTZ-treated, 
MTZ/fhl1b MO-injected, and MTZ/fhl1b-overexpressing embryos/larvae. At 7 dpf, free-
glucose levels were significantly lower in MTZ/fhl1b MO-injected larvae (green line, 512 
pmol/larva) than MTZ-treated (red line, 633 pmol/larva) or MTZ/fhl1b-overexpressing 
(purple line, 742 pmol/larva) larvae. *, P < 0.05; **, P < 0.01; ***, P < 0.001. n = 30 








3.4.2 Identification of TBK1/IKKε inhibitors as enhancers for β-cell 
regeneration in zebrafish 
Considering inhibition of TBK1/IKKε pathway improves insulin sensitivity in 
obese mice (Reilly et al., 2013), and the potential regulatory effect of TBK1/IKKε on 
cAMP via PDE3 (Mowers et al., 2013), we investigated whether TBK1/IKKε pathway is 
directly involved in pancreatic β-cell regeneration. We tested several TBK1/IKKε 
inhibitors in the Tg(ins:CFP-NTR)s892 line, with Tg(ins:Kaede)jh6. MTZ was added at 3 
dpf for 24 hours to induce β-cell apoptosis, followed by washing out of MTZ at 4 dpf, 
and subsequent recovery in the presence or absence of chemical compounds for 48 hours 
(4-6 dpf, corresponding to 0-48 hpa). Interestingly, we observed that the compound 
BX795 can approximately double the number of regenerated β-cells at 48 hpa (Figure 
3.7B and 3.7E). In addition, biologically well-known TBK1/IKKε inhibitor amlexanox 
(Reilly et al., 2013), and a cinnamic acid derivative (E)-3-(3-phenylbenzo[c]isoxazol-5-
yl)acrylic acid (abbreviated as PIAA), identified using a positional scanning peptide 
library (PSPL) technology (Hutti et al., 2012) (originally described as (E)-3-(3-
phenylbenzo[c]isoxazol-6-yl)acrylic acid (iso-PIAA; Figure 3.9A-C)), augmented the 
number of regenerated β-cells even more drastically (Figure 3.7C-E). Among all, PIAA 
showed the highest efficiency (Figure 3.7D-E). These results suggest that inhibition of 





Figure 3.7 TBK1/IKKε inhibition augments β-cell regeneration in zebrafish. 
(A-D) Bright-field images combined with fluorescent images showing the overall 
morphology and [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] expression (green) of larvae at 
48 hpa treated with DMSO (A), BX795 (B), amlexanox (C), and PIAA (D), respectively. 
TBK1/IKKε inhibitors substantially expanded [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6]-
expressing cell population (white squares and insets) during regeneration (B-D) 
compared to DMSO (A). (E) Quantification of the number (mean±SD) of total 
regenerated β-cells at 48 hpa (in A-D; 4.3±1.3 (DMSO), 9.0±2.2 (BX795), 11.0±3.4 
(amlexanox), and 17.7±2.4 (PIAA). n=25 larvae per condition. ***, P < 0.001. 
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To further elucidate the direct involvement of TBK1/IKKε pathway in β-cell 
regeneration, we examined the expression levels of ikbke and tbk1 in various tissues in 
wild-type and β-cell-ablated larvae. mRNA levels of ikbke and tbk1 are substantially and 
specifically elevated in the pancreas upon β-cell ablation (Figure 3.8A-B), suggesting that 







Figure 3.8 Specific expression of TBK1/IKKε in zebrafish pancreas. 
(A-B) qRT-PCR results of ikbke (A) and tbk1 (B) in wild-type or β-cell ablated larvae, 
comparing the fold changes of their expression in relevant tissues/organs. The expression 





To confirm the interactions between TBK1/IKKε and inhibitors, we performed 
molecular docking simulations in collaboration with Oyelere lab, using the well-
characterized TBK1 crystal structure in complex with BX795 (PDB entry 4EUT) (Ma et 
al., 2012). We observed that amlexanox and PIAA adapt docking poses that closely 
mimic the crystallographically obtained structure of BX795 by forming multiple 
hydrogen bonds (H-bonds) with key residues within the kinase domain of TBK1 (Figure 
3.9E-G). The core aromatic moieties, the carboxylate of amlexanox and PIAA, and the 
thiophene amide of BX795 all bound within an unvaried region of the kinase domain 
(Figure 3.9E-G), while BX795, being a longer molecule, used its urea moiety to extend 
toward the outer rim of the kinase domain through interaction with the carbonyl group of 








Figure 3.9 Kinase profiling, and molecular docking analyses reveal selectivity of the 
TBK1/IKKε inhibitors (images C, and E-G provided by Tapadar, S). 
(A-B) Chemical structures and kinase profiling of PIAA and iso-PIAA. Dose responses 
of PIAA and iso-PIAA were generated to determine the potency of the inhibitors (IC50). 
(C) Ball and stick model of PIAA (grey) and iso-PIAA (red) docked into the binding 
pocket of TBK1. PIAA adapts a docked pose that has its isoxazole nitrogen and 
carboxylate moieties engaged in stronger interactions, relative to the same moieties on 
iso-PIAA, with THR-156 and ASP-157 at the active site of TBK1. (D) Chemical 
structures of amlexanox and BX795. (E-G) Molecular docking simulations showing 
interactions of TBK1/IKK -Is and TBK1. Ball and stick model of PIAA (grey), 
amlexanox (blue), and BX795 (purple) docked into the binding pocket of TBK1 (E and 
F). Space filling model of PIAA (grey) and BX795 (purple) docked into the binding 
pocket of TBK1 (G). The core moieties of PIAA, amlexanox, and BX795 all bound 
within an unvaried region of the kinase domain of TBK1, while the urea moiety of 
BX795 extends toward the outer rim of the TBK1 kinase domain and interacts with the 
carbonyl group of Pro-90. Specifically, the carboxylate moieties of PIAA and amlexanox 
are placed next to the carboxylate side chain of ASP-157 buried in the TBK1 active site, 







To corroborate the docking simulations, we further performed structure-activity 
relationship (SAR) studies of PIAA, the most potent β-cell regeneration enhancer among 
those tested. We synthesized three analogs: PIAA-1 (an analog lacking the carboxylate 
group), PIAA-2 (a methyl ester analog of PIAA), and PIAA-3 (an analog with an open 
isoxazolyl ring) (Figure 3.10A-C). The carboxylate group and the intact isoxazolyl ring 
were both required in enhancing β-cell regeneration, since analogs lacking either group 
were inactive (Figure 3.10D). Thus, the SAR data and modeling of TBK1 and inhibitor 
interactions delineate the molecular basis of the selectivity of the TBK1/IKKε inhibitors 
used in in vivo chemical screens. Taken together, these results indicate that suppression 




Figure 3.7 Structure-activity relationship analysis reveals selectivity of the 
TBK1/IKKε inhibitors (images A-C provided by Tapadar, S). 
(A-C) Chemical structures of three PIAA analogs. The moieties that were replaced and 
different from the original PIAA structure are marked in red (PIAA-1 and PIAA-2) or 
blue (PIAA-3). (D) Quantification of the number (mean±SD) of total regenerated β-cells 
at 48 hpa treated with DMSO, PIAA 1, PIAA 2, PIAA 3, and PIAA, respectively 
(4.8±0.8 (DMSO), 4.2±1.3 (PIAA 1), 6.2±1.3 (PIAA 2), 4.0±1.2 (PIAA 3), and 18.6±3.4 
(PIAA)). Cells in 20 planes of confocal images from 10 individual larvae were counted. 
***, P < 0.001. 
 
 105 
3.4.3 TBK1/IKKε inhibitors specifically promote β-cell proliferation 
3.4.3.1Repression of TBK1/IKKε increases β-cell regeneration by primarily 
promoting their proliferation 
To exclude a substantial contribution of pre-existing β-cells to regeneration of β-
cells, we converted the fluorescence of the Kaede protein from green to red by exposing 
the [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae to UV light at 3 dpf immediately after 
MTZ treatment (Figure 3.11A). We found that 48 hpa islets contained only unconverted 
green-only β-cells both in DMSO- or TBK1/IKKε inhibitor-treated recovering larvae 
with a greater number of green-only β-cells in TBK1/IKKε inhibitor-treated larvae 
(Figure 3.11B). These results demonstrate that essentially all β-cells were ablated by 




Figure 3.8 TBK1/IKKε inhibition augments β-cell regeneration in zebrafish. 
(A) Schematic diagram for assessment of ablation efficiency of β-cells. (B) 
Quantification of the number (mean±SD) of newly regenerated (Green+) β-cells at 48 hpa 
(4.4±1.6 β-cells were green-only-positive in DMSO-treated larvae, while 9.3±2.2 
(BX795), 11.1±4.4 (amlexanox), and 18.1±3.6 (PIAA) β-cells expressed as green-only in 
TBK1/IKKε inhibitor-treated recovering larvae). Cells in 20 planes of confocal images 
from 10 individual larvae were counted. ***, P < 0.001. 
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The TBK1/IKKε inhibitor-induced increase in the number of newly regenerated 
β-cells could result from enhanced proliferation of β-cells, stimulation of neogenesis 
from non-β-cells, or both (Baeyens et al., 2014; Dor et al., 2004; Thorel et al., 2010; Xu 
et al., 2008). Hence, we determined the effect of TBK1/IKKε suppression on β-cell 
proliferation by performing cell cycle analysis with the replication marker 5-ethynyl-2’-
deoxyuridine (EdU). [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae were treated with 
MTZ from 3–4 dpf to ablate the β-cells, and subsequently treated with EdU and DMSO 
or TBK1/IKKε inhibitors for 48 hours (4-6 dpf, corresponding to 0-48 hpa). The number 
of β-cells that incorporated EdU was significantly greater in TBK1/IKKε inhibitor-treated 












Figure 3.9 TBK1/IKKε inhibitors promote β-cell replication. 
(A-D) Confocal images of [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae at 48 hpa, 
concurrently treated with EdU and DMSO (A), BX795 (B), amlexanox (C), or PIAA (D), 
respectively, from 0-48 hpa. The number of β-cells that incorporated EdU (white arrows) 
was substantially increased in TBK1/IKKε inhibitor-treated recovering larvae (B-D) 
compared to DMSO-treated larvae (A). (E) Quantification of the number (mean±SD) of 
total regenerated β-cells (green bars) and regenerated β-cells that incorporated EdU 
(yellow bars) at 48 hpa (in A-D; 5.0±1.3 total regenerated β-cells, of which 0.7±0.5 
(DMSO), 11.0±3.4, of which 4.6±1.8 (BX795), 12.8±4.8, of which 5.2±2.8 (amlexanox), 
and 20.6±3.1, of which 11.0±1.9 (PIAA) incorporated EdU). (F) The percentage 
(mean±SD) of regenerated β-cells that incorporated EdU at 48 hpa (in A-D; 13.0±11.0% 
(DMSO), 42.0±5.0% (BX795), 39.0±7.0% (amlexanox), and 55.0±14.0% (PIAA)). Cells 
in 20 planes of confocal images from 10 individual larvae were counted. **, P < 0.01; 






A previous study showed that β-cell neogenesis occurs through both α-to-β-cell 
transdifferentiation and ductal progenitor-to-β-cell conversion during the initial stages of 
regeneration in zebrafish (Ye et al., 2015). Administering TBK1/IKKε inhibitors, 
specifically amlexanox and PIAA, for 24 hours (from 4-5 dpf) rather than for 48 hours 
(from 4-6 dpf), caused a slight increase in the number of cells that co-express Insulin and 
Glucagon (Figure 3.13E-H). There was minimal enhancement of the number of β-cells 
in/adjacent to the hepatopancreatic ductal (HPD) system and that of cells co-expressing 
Insulin and Somatostatin (Figure 3.13A-D). These results indicate that TBK1/IKKε 
repression does not primarily affect β-cell neogenesis.  
To further test whether these compounds increase proliferation of newly formed 
β-cells, we introduced a transitional day between β-cell ablation and TBK1/IKKε 
inhibitor treatment. This time lag allowed MTZ-induced ablation to conclude and the 
default neogenesis to begin before the compounds were added. Amlexanox and PIAA 
both potently increased the number of EdU incorporated β-cells with the transitional day 
(Figure 3.14A-B). Taken together, these data suggest that TBK1/IKKε suppression 




Figure 3.10 TBK1/IKKε inhibitors have modest effects on α-to-β-cell 
transdifferentiation. 
(A-C) Confocal images of [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae at 24 hpa, 
concurrently treated with EdU and DMSO (A), amlexanox (B), or PIAA (C), 
respectively, from 0-24 hpa, stained for Somatostatin (blue). (D) Quantification of the 
number (mean±SD) of Insulin and Somatostatin-double positive cells at 24 hpa (in A-C; 
0.7±0.6 (DMSO), 1.7±0.8 (amlexanox), and 1.8±0.5 (PIAA)). (E-G) Confocal images of 
[Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae at 24 hpa, concurrently treated with EdU 
and DMSO (E), amlexanox (F), or PIAA (G), respectively, from 0-24 hpa, stained for 
Glucagon (blue). Note that the number of Insulin and Glucagon-double positive cells 
(blue arrows) was increased in TBK1/IKKε inhibitor-treated recovering larvae (F and G) 
compared to DMSO-treated larvae (E). PIAA-treated larvae also showed an EdU-
incorporated β-cell (white arrow) (G). (H) Quantification of the number (mean±SD) of 
Insulin and Glucagon-double positive cells at 24 hpa (in E-G; 1.5±1.1 (DMSO), 3.4±1.3 
(amlexanox), and 4.4±1.9 (PIAA)). Cells in 20 planes of confocal images from 10 





Figure 3.11 TBK1/IKKε inhibitors strongly enhance β-cell proliferation. 
(A-C) Confocal images of [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae at 48 hpa, 
concurrently treated with EdU and DMSO (A), amlexanox (B), or PIAA (C), 
respectively, from 24-48 hpa. The number of β-cells that incorporated EdU (white 
arrows) was significantly increased in TBK1/IKKε inhibitor-treated recovering larvae (B 
and C) compared to DMSO-treated larvae (A). (B) The percentage (mean±SD) of 
regenerated β-cells that incorporated EdU at 48 hpa (in A-C; 4.0±7.0% (DMSO), 
32.0±6.0% (amlexanox), and 39.0±6.0% (PIAA)). Cells in 20 planes of confocal images 














3.4.3.2 TBK1/IKKε inhibition selectively accelerates proliferation of β-cells 
To determine whether TBK1/IKKε inhibitors increase proliferation of β-cells 
specifically or whether they trigger a general increase in cell proliferation, we assessed 
the replication rate of other pancreatic endocrine cells and tissues, specifically 
Somatostatin-producing δ-cells, Glucagon-producing α-cells, and liver cells. Inhibition of 
TBK1/IKKε led to minimal increase of EdU incorporation in δ-cells, whereas it enhanced 
proliferation of β-cells in the regenerating pancreas (Figure 3.15A-D). TBK1/IKKε 









Figure 3.12 TBK1/IKKε inhibitors selectively increase the number of β-cells. 
(A-C) Confocal images of [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae at 48 hpa, 
concurrently treated with EdU and DMSO (A), amlexanox (B), or PIAA (C), 
respectively, from 0-48 hpa, stained for Somatostatin (blue). The number of 
Somatostatin-expressing δ-cells that incorporated EdU (purple arrows) did not increase in 
TBK1/IKKε inhibitor-treated recovering larvae (B and C) compared to DMSO-treated 
larvae (A). (D) The percentage (mean±SD) of δ-cells that incorporated EdU at 48 hpa (in 
A-C; 12.9±2.0% (DMSO), 12.4±4.7% (amlexanox), and 15.1±4.3% (PIAA)). Cells in 20 
planes of confocal images from 10 individual larvae were counted. (E-G) Confocal 
images of [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae at 48 hpa, concurrently treated 
with EdU and DMSO (E), amlexanox (F), or PIAA (G), respectively, from 0-48 hpa, 
stained for Glucagon (blue). The number of Glucagon-expressing α-cells that 
incorporated EdU (blue arrows) did not increase in TBK1/IKKε inhibitor-treated 
recovering larvae (F and G) compared to DMSO-treated larvae (E). (H) The percentage 
(mean±SD) of α-cells that incorporated EdU at 48 hpa (in E-G; 6.2±2.4% (DMSO), 
8.0±1.9% (amlexanox), and 10.9±3.4% (PIAA)). Cells in 20 planes of confocal images 





Furthermore, there was no considerable difference between DMSO- and 
TBK1/IKKε inhibitor-treated larvae on the number of liver cells that incorporated EdU 






Figure 3.13 TBK1/IKKε inhibitors do not increase proliferation of liver cells. 
(A-C) Confocal single-plane images of [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] larvae at 
48 hpa, concurrently treated with EdU and DMSO (A), amlexanox (B), or PIAA (C), 
respectively, from 0-48 hpa, stained for Prox1 (blue). The number of Prox1-positive cells 
in the liver that incorporated EdU did not significantly increase in TBK1/IKKε inhibitor-
treated recovering larvae (B and C) compared to DMSO-treated larvae (A). (D) The 
percentage (mean±SD) of Prox1-positive liver cells that incorporated EdU at 48 hpa (in 
A-C; 31.6±5.6% (DMSO), 30.1±5.8% (amlexanox), and 33.5±10.5% (PIAA)). Cells in 




A longer treatment with TBK1/IKKε inhibitors, for 96 hours after β-cell ablation, 
showed that TBK1/IKKε inhibitor treatment did not lead to an overshoot in β-cell 
number (Figure 3.17). These results suggest that suppression of TBK1/IKKε enhances β-
cell proliferation during the most dynamic period of β-cell regeneration without inducing 




Figure 3.14 TBK1/IKKε inhibitors do not lead to an overshoot in β-cell number. 
(A-C) Bright-field images combined with fluorescent images showing the overall 
morphology of embryos and [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] expression (green) 
in larvae at 96 hpa treated with DMSO (A), amlexanox (B), and PIAA (C), respectively. 
While TBK1/IKKε inhibitors treatment expanded [Tg(ins:CFP-NTR)s892; 
Tg(ins:Kaede)jh6]-expressing cell population (white squares and insets) during 
regeneration (B and C) compared to DMSO (A), a longer treatment (0-96 hpa) did not 
result in overproliferation of β-cells. (D-F) Confocal single-plane images of [Tg(ins:CFP-
NTR)s892; Tg(ins:Kaede)jh6] larvae at 96 hpa (in A-C), stained with Topro (blue). White 
arrows indicate β-cells located in secondary islets. 
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Next, we examined the ability of TBK1/IKKε inhibitors to restore 
normoglycemia. Free glucose levels were elevated after β-cell ablation, but declined from 
24-72 hpa (corresponding to 5-7 dpf) in DMSO- and TBK1/IKKε inhibitor-treated larvae. 
Importantly, normal levels of free glucose were recovered significantly faster in 
TBK1/IKK -I-treated, especially PIAA-treated, larvae than in DMSO-treated larvae 
(Figure 3.18). Altogether, these data suggest that inhibition of TBK1/IKKε induces 




Figure 3.15 TBK1/IKKε inhibitors accelerate restoration of β-cell function. 
Free-glucose levels (mean±SD) during β-cell regeneration in non-ablated wild type, 
DMSO-treated recovering, and TBK1/IKKε inhibitor-treated recovering larvae. At 7 dpf, 
free-glucose levels were significantly lower in PIAA-treated recovering larvae (blue line, 
457.7±28.8 pmol/larva) than in DMSO-treated larvae (purple line, 719.3±42.2 
pmol/larva). *, P < 0.05. n = 30 larvae (3 pools of 10 larvae) per data point. 
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3.4.3.3 Repression of TBK1/IKKε enhances β-cell replication via cAMP activation 
Given the previous studies showing increased cAMP levels in adipocytes induced 
by inhibition of TBK1/IKKε (Mowers et al., 2013), and direct phosphorylation and 
activation of PDE3B in vitro by TBK1 and IKKε (Mowers et al., 2013), we hypothesized 
that inhibition of TBK1/IKKε induces the activity of the cAMP for β-cell regeneration 
via suppression of a TBK1/IKKε-PDE3 signaling axis (Figure 3.19A). To test this 
hypothesis, we first measured the cellular cAMP levels in the PIAA-treated regenerating 
larvae. Treatment with PIAA led to pronounced increases in cAMP levels (Figure 3.19B). 
Furthermore, we assessed the effects of ectopic expression of pde3a on mitogenic 
potential of inhibition of TBK1/IKKε using a heat-inducible transgene Tg(hsp:pde3a; 
hsp:GFP)gt4. Pde3a is the only PDE3 isoform in zebrafish and its expression is 
significantly and specifically elevated in the pancreas upon β-cell ablation (Figure 
3.19C).  
When pde3a expression was induced during recovery period in the presence of 
PIAA, the proportion of new β-cells that proliferate was decreased compared to PIAA-
only-treated larvae (Figure 3.20B-D). These data suggest that suppression of TBK1/IKKε 
bestows an increase in β-cell number by regulating cAMP activity through PDE3 in the 




Figure 3.16 The TBK1/IKKε-PDE3-cAMP signaling axis during β-cell regeneration. 
(A) Schematic of the TBK1/IKKε-PDE3 signaling that modulates cAMP levels. (B) 
Quantification of cAMP levels (mean±SD) at 48 hpa (0.4±0.1 pmol/larva (DMSO) and 
0.9±0.0 pmol/larva (PIAA)). (C) qRT-PCR results of pde3a in wild-type or β-cell ablated 
larvae, comparing the fold changes of their expression in relevant tissues/organs. The 
expression levels of pde3a are significantly and specifically elevated in the pancreas upon 







Figure 3.17 Suppression of the TBK1/IKKε-PDE3 signaling axis promotes β-cell 
proliferation. 
(A-D) Confocal images of EdU-administered [Tg(ins:CFP-NTR)s892; Tg(ins:Kaede)jh6] 
larvae at 48 hpa, treated with DMSO (A) and PIAA (C), respectively, or induced pde3a 
expression upon β-cell ablation (B) and pde3a expression upon β-cell ablation in the 
presence of PIAA (D), respectively, from 0-48 hpa. The number of EdU-incorporated 
(white arrows) β-cells was increased in recovering larvae treated with PIAA (C) 
compared to DMSO-treated larvae (A). When pde3a expression was induced upon β-cell 
ablation, PIAA-dependent increases in the number of EdU-incorporated β-cells were 
suppressed (D). (E) Quantification of the number (mean±SD) of total regenerated β-cells 
(green bars) and regenerated β-cells that incorporated EdU at 48 hpa (in A-D; 4.8±1.2 
total regenerated β-cells, of which 0.6±0.6 (DMSO), 4.0±1.0, of which 0.5±0.5 (pde3a 
overexpressing), 17.8±2.8, of which 8.9±2.0 (PIAA), and 8.0±2.8, of which 1.7±1.2 
(pde3a overexpressing in the presence of PIAA)). (F) The percentage (mean±SD) of 
regenerated β-cells that incorporated EdU at 48 hpa (in A-D; 9.4±10.5% (DMSO), 
8.8±11.6% (pde3a overexpressing), 46.5±8.3% (PIAA), and 16.1±10.5% (pde3a 
overexpressing in the presence of PIAA)). Cells in 20 planes of confocal images from 10 
individual larvae were counted. ***, P < 0.001. 
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3.4.4 TBK1/IKKε inhibition augments β-cell function and proliferation in 
mammalian systems 
To determine whether the effects of TBK1/IKKε suppression on β-cells are 
conserved across species, we collaborated with Garcia lab and first performed glucose-
stimulated insulin release (GSIR) assay in primary rat and human islets as elevation of 
cAMP levels has shown to lead to both improved insulin secretion and enhanced 
replication of β-cells (Inada et al., 2004; Xie et al., 2007; Zhao et al., 2014). PIAA 
treatment significantly increased glucose stimulation indices in rat and human islets 
(Figure 3.22D and 3.23D). Next, we investigated mitogenic effect of TBK1/IKKε 
inhibition by analyzing the ability of TBK1/IKKε inhibitors to increase β-cell 
proliferation in INS-1 rat pancreatic β-cells. Treating INS-1 cells with PIAA resulted in 
increased percentage of proliferating Insulin-positive cells (co-expressed Ki-67) (Figure 
3.21A-C), and cAMP levels (Figure 3.21D), suggesting that suppression of TBK1/IKKε 





Figure 3.18 PIAA induces proliferation of cultured rat β-cells. 
(A-B’) Confocal images of rat INS-1 β-cells treated with DMSO (A-A’) and PIAA (B-
B’), respectively, stained for Ki67 (red) and Insulin (green). (C) The percentage 
(mean±SD) of Ki67 and Insulin-double positive cells (in A-B’; 43.1±5.2% (DMSO) and 
87.3±10.4% (PIAA)). (D) Quantification of cAMP levels (mean±SD) (5.8±0.2 pmol/well 





PIAA increased β-cell proliferation in whole rat islets in a dose-dependent manner 
(Figure 3.22A-C).  Importantly, treatment of PIAA on primary human β-cells using islets 
obtained from 3 cadaveric organ donors caused a notable, dose-dependent induction of β-




Figure 3.19 PIAA induces proliferation of cultured rat islets (image D provided by 
Weaver, J). 
(A-B’) Confocal single-plane images of whole rat islets treated with DMSO (A-A’) and 
PIAA (B-B’), respectively, stained for Ki67 (red, white arrows) and Insulin (green). (C) 
The percentage (mean±SD) of Ki67 and Insulin-double positive cells in whole rat islets 
increased in a dose-dependent manner with treatment of PIAA (1.1±0.3% (DMSO), 
2.7±0.9% (20 µM), 3.7±1.5% (40 µM), and 5.5±0.6% (80 µM)). n=5 replicates per 
condition.  (D) Glucose stimulation indices of rat islets treated with DMSO or PIAA (300 






Figure 3.20 PIAA induces proliferation of cultured human islets (image D provided 
by Weaver, J). 
(A-B’) Confocal single-plane images of human islets treated with DMSO (A-A’) and 
PIAA (B-B’), respectively, stained for Ki67 (red, white arrows), Topro (blue), and 
INSULIN (green). (C) The percentage (mean±SD) of Ki67 and Insulin-double positive 
cells in human islets increased in a dose-dependent manner with treatment of PIAA 
(0.1±0.0% (DMSO), 0.3±0.1% (20 µM), 0.4±0.1% (40 µM), and 0.5±0.2% (80 µM)). 
n=5 replicates per condition from 3 cadaveric donors.  (D) Glucose stimulation indices of 
human islets treated with DMSO or PIAA (300 islet equivalents per column, triplicate). 








We further investigated whether PIAA could increase β-cell regeneration in the 
streptozotocin (STZ)-induced mouse model of type I diabetes. First we checked if 
TBK1/IKKε exhibit distinct expression pattern in mouse tissues. Indeed, Ikbke and Tbk1 
show prominent basal and induced expression in the pancreas and white adipose tissue 






Figure 3.21 Prominent expression of TBK1/IKKε in murine pancreas and white 
adipose tissue. 
(A-B) qRT-PCR results of Ikbke and Tbk1 in wild-type or STZ-induced diabetic mice, 
comparing the fold changes of their expression in relevant tissues/organs. Ikbke and Tbk1 
show prominent basal and induced expression in the pancreas and white adipose tissue 
(WAT) upon STZ treatment. n=3 mice per group, triplicate. 
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PIAA administration caused a substantial reduction of non-fasting blood glucose 
levels after 4-5 days of intraperitoneal injection (Figure 3.25A). Significant improvement 





Figure 3.22 PIAA improves glucose control in the STZ-induced diabetes murine 
model. 
(A-B) STZ-induced diabetic mice were treated with vehicle or PIAA for 8 days after 
disease induction (n=6 mice per group). (A) PIAA caused reduction of hyperglycemia 
(fed glucose measurement) relative to vehicle-treated animals. (B) PIAA-treated animals 







Morphometric analysis of pancreas sections showed that the β-cells, not α-cells, in 
PIAA-treated mice were more likely to be Ki67+, indicating that they were proliferating 
at a higher rate (Figure 3.26A-C). Moreover, β-cell area and insulin content were 
increased in PIAA-treated compared with vehicle-treated diabetic mice (Figure 3.26D-E). 
PIAA treatment also increased cAMP levels in the pancreas (Figure 3.26F). Taken 
together, these data suggest that inhibition of TBK1/IKKε leads to improvement of β-cell 
function and induction of β-cell replication across multiple species including primary 














Figure 3.23 PIAA improves β-cell mass in the STZ-induced diabetes murine model. 
(A-F) STZ-induced diabetic mice were treated with vehicle or PIAA for 8 days after 
disease induction (n=6 mice per group). Confocal images of diabetic pancreata treated 
with (A) vehicle and (B) PIAA, respectively, stained for Ki67 (red, white arrows), Insulin 
(green), and Glucagon (blue). (C) The percentage (mean±SD) of Ki67 and Insulin-double 
positive cells in diabetic islets increased with PIAA treatment (0.7±1.0% (vehicle) and 
3.1±1.2% (PIAA)). Quantification (mean±SD) of (D) β-cell area (fold change, 1.0±0.3 
(vehicle) and 1.9±0.1 (PIAA)), (E) insulin content (51.8±1.9 µg/g (vehicle) and 
114.0±37.7 µg/g (PIAA)), and (F) cAMP levels (2.0±0.2 pmol/mg (vehicle) and 5.5±1.0 
(PIAA)) in diabetic pancreata treated with vehicle or PIAA. *, P < 0.05; **, P < 0.01; 








In the progenitors residing in the HPD system at later stages, Fhl1b regulates 
induction of pancreatic endocrine cells and regeneration of β-cells. Suppression of fhl1b 
increased pdx1 and neurod expression in HPD progenitors, augmenting pancreatic 
endocrine cell formation and β-cell regeneration, whereas overexpression of fhl1b 
inhibited induction of pancreatic endocrine cells and β-cell regeneration.  
We also identified TBK1/IKKε inhibitors as selective enhancers of β-cell 
proliferation in a transgenic zebrafish model of type I diabetes. We further demonstrated 
that inhibition of TBK1/IKKε promotes amplification of β-cells in mammalian systems 
including primary rat and human islets as well as STZ-induced diabetic mice. The 
proliferative effects of TBK1/IKKε inhibitors are likely to be mediated by the cAMP 
signaling via PDE3, indicating that TBK1/IKKε play a previously unappreciated role in 
modulating β-cell mass. 
 
3.6 Discussion 
Previous studies have suggested evident plasticity of cells in the HPD system, 
where differentiation into a specific lineage is suppressed by Fgf10 and Sox9b in 
zebrafish (Delous et al., 2012; Dong et al., 2007; Manfroid et al., 2012). Furthermore, 
expression analysis of Id2 has shown that Bmp signaling is blocked and/or excluded in 
the tissues, including those of the HPD system, that retain the potential to form pancreatic 
endocrine cells (Chung et al., 2010). Our data provide the intriguing evidence that Bmp2b 
signaling controls the induction of pancreatic endocrine cells from the HPD system by 
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inhibiting pdx1 expression through its effector Fhl1b. The reciprocal expression pattern 
of fhl1b and pdx1 further supports the suppressive effect of Fhl1b on pdx1 expression. At 
3 dpf, liver cells, which never express pdx1 in lineage tracing analyses in mice (Fujitani 
et al., 2006; Gu et al., 2002) and in zebrafish (Chung et al., 2008), express high levels of 
fhl1b, while the HPD system expresses low levels of fhl1b. Consistently, the proximal 
intestine, which has been shown to have marked plasticity (Dong et al., 2007), expresses 
low levels of fhl1b. Most pancreatic cells do not express fhl1b except for a few cells in 
the principal islet. Intriguingly, these few pancreatic cells are located in the peripheral 
boundary of the principal islet, but are not overlapping with the core β-cells, which 
maintain a high-level of pdx1 expression. Manipulating this antagonistic interplay may 
direct a common endodermal progenitor pool towards pancreatic endocrine, specifically 
β-cell, fate by modulating distinct levels of pdx1 expression.   
While the intrinsic transcriptional network that regulates β-cell development is 
well identified (Arda et al., 2013; Pan and Wright, 2011), the extrinsic signaling 
pathways that control β-cell regeneration remain largely elusive. Our studies for the first 
time suggest that Bmp signaling plays an essential role in the regeneration of β-cells, in 
part by modulating pdx1 and neurod expression in the HPD system through its regulator 
Fhl1b. Although we are not able to exclude the possibility that newly generated β-cells 
came from α-cells (Thorel et al., 2010), our loss-of-function analyses of Fhl1b during 
normal development imply that increased formation of endocrine progenitors may lead to 
enhanced β-cell regeneration. In line with this hypothesis, in β-cell ablated fhl1b MO-
injected larvae, multiple regenerating β-cells were found at the junction between the 
pancreas and the HPD system. In contrast, Adenosine signaling, one of the few signals 
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that has been shown to function during β-cell depletion in zebrafish (Andersson et al., 
2012), plays a significant role in regulating β-cell mass during regeneration but not 
during normal conditions. Careful dissection of extrinsic signals and intrinsic factors 
acting on a specific aspect of β-cell regeneration will allow us to perform individual or 
combinatorial therapies to pinpoint the most valid regeneration strategy. 
For the first time, we have pinpointed that inhibition of TBK1/IKKε promotes β-
cell proliferation in multiple species including primary human islets. Of essential 
importance is that suppression of TBK1/IKKε with amlexanox and PIAA, which 
exhibited the highest potency among tested, can increase β-cell proliferation selectively 
without inducing a general increase in proliferation of other cell types/tissues and that a 
longer treatment with these small molecules did not lead to overproliferation of β-cells 
once normoglycemia was approached. Since oncogenicity can arise as a result of 
modulating mitogenic or regenerative pathways (Wang et al., 2015b), specific 
TBK1/IKKε inhibitors’ selectivity to β-cells and ability to increase β-cell proliferation 
primarily during the most active period of β-cell regeneration present valid strategies for 
expanding β-cell mass. Furthermore, our results may support that Diarylamide WS6, 
which was previously suggested to target IKKwith increasing -cell proliferation 
potency in primary human islet culture (Boerner et al., 2015; Shen et al., 2013), had 
modest effect on human β-cell proliferation (Wang et al., 2015a). Therefore, further 
design and validation of new molecular structures with potent TBK1- and/or IKKε- 
inhibition activities and minimal toxicity using the PIAA as a scaffold will allow us to 
identify legitimate strategies for developing human β-cell-specific proliferogens.  
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In progression of T1DM and T2DM, which is the most prevalent form of 
diabetes, decreasing β-cell mass is a common feature. T2DM patients with impaired 
fasting glucose show a relatively reduced β-cell mass regardless of obesity. This 
characteristic highlights a critical urgency to develop strategies to expand functionally 
relevant β-cell mass in diabetic therapy. TBK1/IKKε have shown to mainly act on IRFs, 
specifically IRF-3 and IRF-7, that are crucially involved in innate and adaptive immune 
responses and in pathogenesis of autoimmune diseases (Sharma et al., 2003). In the 
presence of IRF-induced type I interferon (IFN) (Honda et al., 2005; Sato et al., 2000), 
IKKε phosphorylates the Signal Transducer and Activator of Transcription 1 (STAT1) 
protein (Tenoever et al., 2007), which is critical to promote apoptosis upon viral 
infection. Accordingly, it is plausible to speculate that suppression of TBK1/IKKε can 
preserve residual β-cells in part by inhibiting STAT1-induced apoptosis.  As our analyses 
suggest that repression of TBK1/IKKε increases the number of β-cells by stimulating 
cAMP, a careful dissection and elucidation of TBK1/IKKε-controlled signaling networks 
will shed light on modulating the immune response with concomitant increase in β-cell 







CONCLUSION AND DISCUSSION 
The work in this thesis identified fhl1b as a novel target of Bmp2b signaling. By 
expression analysis, loss-of-function and gain-of-function studies, we showed that fhl1b 
promotes specification of liver and suppresses induction of pancreatic cells. Combined 
with single-cell lineage tracing experiments, we indicated that manipulation of fhl1b 
levels in the progenitors could lead to fate switch of endodermal progenitors. 
Furthermore, Fhl1b also regulates the regeneration of β-cells by modulating pdx1 
and neurod expression in the HPD system. Loss-of-function and gain-of-function studies 
suggested fhl1b mainly regulates the neogenesis of β-cells from the progenitor cell 
population residing in the HPD system.  
In addition to Bmp2b signaling pathway, we identified TBK1/IKKε inhibitors as 
enhancers of β-cell regeneration. These inhibitors promoted β-cell regeneration through 
enhancing β-cell-specific proliferation. Our results also suggested that this effect is 
achieved by up-regulating cAMP levels via suppressing activation of Pde3a in zebrafish. 
This effect is conserved in mammalian islets culture and STZ-induced diabetic mice.  
These data firstly described the function of Fhl1b as a Bmp2b downstream target, 
regulating the fate decision of endodermal progenitor cells. It also supports the 
speculation that besides actively initiating the expression of hepatic lineage program, 
Bmp signaling may actively suppress the onset of pancreatic lineage gene expression. 
These data provide novel insights in β-cell regeneration as well. As previously expected, 
various sources can contribute to β-cell regeneration. Here we showed that two of them, 
the progenitors in the ductal system and the remaining endogenous β-cells, can be 
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regulated by signaling pathways. Depletion of fhl1b resulted in more progenitors 
converting to β-cells upon injury. This knowledge can also be applied to induce the 
directed differentiation of progenitor cells in vitro. The new connection between 
suppression of TBK1/IKKε pathway and β-cell proliferation during regeneration opened 
many possibilities for future treatment development.  
It is important to further uncover how Bmp signaling pathway, especially through 
Fhl1b, regulates the fate decision process. A few studies linked the roles of Bmp 
signaling in fate decision with alterations of chromatin states and histone modifications. 
It’s suggested that Bmp activates liver gene expression by recruiting factors to induce 
histone acetylation in the regulatory regions of liver genes. The pancreatic gene 
regulatory elements are poised by both active and suppressive histone marks. Loss of the 
suppressive marks led to pancreatic gene activation. These studies indicate that epigenetic 
modulation of lineage specification gene program is another layer of regulation in liver 
and pancreas fate decision. And Bmp is involved in this layer as well. Considering the 
characters of LIM-domain-only proteins, it is reasonable to speculate that Fhl1b may 
participate in epigenetic regulation of the histone marks via protein-protein interaction 
with some other histone modifying complexes. To answer this question, it would be very 
necessary and useful to identify proteins and factors binding with Fhl1b. Meanwhile, 
investigation of binding sites of Fhl1b in the genome could potentially tell the gene 
programs regulated by Fhl1b. By comparing the histone modification marks at those sites 
using control and altered-fhl1b-level samples, we can gain clues on how this regulation is 
achieved.   
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To exploit the potential of TBK1/IKKε inhibitors in future diabetes treatment, 
there are a few more questions need to be answered. First, a genetic validation is 
necessary to fully support the results from inhibitor treatment, and to provide confidence 
in exploring possible novel targets in this pathway. Nevertheless, the downstream 
network and effectors of TBK1/IKKε are not clear yet. Dissecting the regulatory 
pathways may help us to better understand the mechanism and specificity of this 
proliferative effect on β-cell regeneration. A few more screenings on inhibitors 
suppressing β-cell proliferation could provide information on possible downstream 
effectors. The discoveries of more downstream targets could also contribute to 
identifying new therapy strategies. The exploration of the immunosuppression side of 
TBK1/IKKε inhibitors will be an interesting mission and may lead to the development of 
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